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ABSTRACT 
 Substance abuse disorders are heritable neuropsychiatric disorders with 
largely unknown genetic etiology. Distinct genetic factors likely contribute to the 
different stages and behaviors of addiction, including initial sensitivity to the 
subjective and physiological effects of drugs and physiological and psychological 
measures of withdrawal. Mammalian model organisms permit a comprehensive 
approach to gene mapping and to bridging genetic variation with neurobiological 
mechanisms of addiction-relevant behaviors. The focus of this dissertation is to 
investigate the genetic basis of the rewarding and aversive properties of opioids, 
utilizing a systems genetics approach that includes both forward and reverse 
genetics in combination with transcriptomics and bioinformatics as tools to 
determine the molecular mechanisms. 
 The first aim of this research is to conduct a genetic linkage mapping 
study of addiction-associated traits in a reduced complexity cross of two nearly 
identical B6 substrains (C57BL/6J and C57BL/6NJ). Forward genetic techniques, 
such as quantitative trait locus (QTL) mapping was utilized to identify novel 
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candidate genes involved in addiction-associated traits. We completed QTL 
mapping combined with genome-wide gene expression analyses to rapidly 
identify compelling candidate genes underlying addiction traits. Most notably, we 
identified a region on distal chromosome 1 that regulates opioid sensitivity and 
withdrawal. Using striatal expression QTL mapping, transcript/behavior 
covariance, and convergent haplotype analysis, we identified a strong positional 
candidate gene, Rgs7. 
 The second aim of this research is to validate novel candidate genes and 
molecular mechanisms responsible for modulation of opioid reward and aversion. 
Using behavioral and expression QTL mapping, Csnk1e was previously identified 
as a candidate gene for psychostimulant sensitivity. Here, we utilized Csnk1e 
knockout mice to confirm the effect of Csnk1e deletion on opioid sensitivity and 
extend its role to opioid reward and a natural reward dependent on opioid 
signaling- sweetened palatable food consumption. Additionally, we have utilized 
striatal transcriptome analyses to identify potential molecular mechanisms, 
including aberrant myelination and neurodevelopment of the striatum. 
 In summary, this dissertation research utilizes mouse forward and reverse 
genetics, in combination with transcriptome and bioinformatics analyses to 
identify the genetic and neurobiological underpinnings of addiction-associated 
traits. 
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PREFACE 
All experiments outlined in this dissertation are organized in the format of 
manuscripts prepared for submission. 
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CHAPTER ONE: Introduction 
Addiction 
Socioeconomic impact 
 Substance abuse disorders represent a significant public health concern in 
the United States. In 2015, an estimated 27.1 million Americans had abused an 
illicit drug within the past month (Substance Abuse and Mental Health Services 
Administration, 2016). Moreover, approximately 7.7 million Americans had been 
diagnosed with a substance use disorder within the last year (SAMHSA, 2016). 
Illicit drug use is associated with numerous adverse health effects and can be 
damaging to the individual (Degenhardt et al., 2013). Furthermore, substance 
abuse places a large economic burden on the United States, with an estimated 
cost of $193 billion in 2007 due to increased health care, and law enforcement 
costs paired with decreased work productivity of the affected individuals (Oderda, 
Lake, Rudell, Roland, & Masters, 2015). These numbers highlight that drug 
abuse is a significant public health concern in the United States. 
 Opioid abuse, specifically, has reached epidemic levels in the United 
States (Manchikanti et al., 2012; Okie, 2010). Opioids, a highly addictive class of 
drugs, include illicit drugs such as heroin, as well as prescription drugs such as 
oxycodone, fentanyl, and morphine (Wallace & Yaksh). Widespread prescribing 
of opioid analgesics in the United States has contributed to their diversion to non-
medical, recreational use. Prescription opioid misuse alone has been estimated 
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to produce an economic impact of at least $50 billion in the US (Birnbaum et al., 
2011; Oderda et al., 2015). Although the reformulation of oxycodone to an 
abuse-deterrent form (Oxycontin ®) has helped decrease abuse, Americans 
continue to initiate misuse of prescription opioids, with an estimated 2.1 million 
new misusers in 2015, which is more than double the amount of new users of 
cocaine (Lipari, Williams, Copello, & Pemberton, 2016). Additionally, this 
reformulation resulted in a switch to illicit opioids (i.e. heroin) (Cicero & Ellis, 
2015; Volkow & McLellan, 2016), which may be less costly and more easily 
acquired (Unick, Rosenblum, Mars, & Ciccarone, 2014). As a result of this shift, 
there was a nearly 150% increase in heroin use from 2007 to 2014 (Substance 
Abuse and Mental Health Services Administration, 2015). This steep rise in 
heroin use has consequently resulted in a steep rise in heroin overdose deaths, 
which increased five-fold from 2000 to 2014 (Centers for Disease Control and 
Prevention, 2015).  
Current Treatments 
 Substance use disorders (SUDs) comprise the addictions and are chronic, 
relapsing, psychiatric disorders defined by compulsive use despite negative 
consequences (American Psychiatric Association, 2013). Current treatment 
options for SUDs are extremely limited. For methamphetamine addiction, the 
standard-of-care is either inpatient or outpatient behavioral programs (Brensilver, 
Heinzerling, & Shoptaw, 2013).  Although these treatments can be effective, the 
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overall impact is low, resulting in high relapse rates. Furthermore, there are no 
FDA-approved pharmacological treatments for methamphetamine addiction. 
 Current treatments for opioid addiction are limited and focus on controlling 
the symptomatology (Lobmaier, Gossop, Waal, & Bramness, 2010). These 
treatments fall into two categories: opioid replacement therapy and opioid 
intoxication/overdose treatment. Opioid replacement therapy requires daily 
treatment with an opioid agonist (most commonly methadone) that exhibits 
limited euphoric effects. The goal of this treatment is to decrease craving, limit 
withdrawal symptoms, and avoid illicit drug use and the negative consequences 
associated with such use (Lobmaier et al., 2010). Opioid intoxication/overdose 
treatment utilizes a mu opioid receptor competitive antagonist, naloxone, to 
reverse intoxication or prevent death by overdose (Lobmaier et al., 2010). 
Although these treatments display efficacy, they treat the symptoms of the 
disease rather than the disease itself. Lack of efficient treatments, in combination 
with increases in opioid-related deaths necessitates a more complete 
understanding of the neurobiological mechanisms associated with the transition 
from casual drug use to addiction. 
Stages of Addiction 
 The addiction process is composed of progressive stages of behavior, 
beginning with initial use and transitioning to regular, and later, compulsive use 
(Hyman & Malenka, 2001; Piazza & Deroche-Gamonet, 2013). This shift from 
recreational to compulsive use of drugs of abuse is mediated by an increase in 
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motivation to obtain drugs of abuse and a decrease in the rewarding properties of 
drugs as well as natural reinforcers (Adinoff, 2004; Koob & Volkow, 2010).  
Addiction can be conceptualized as consisting of three main stages: 
binge/intoxication, withdrawal/negative affect, and preoccupation/anticipation 
(Koob & Le Moal, 2008a, 2008b; Koob & Volkow, 2010).  The binge/intoxication 
phase of addiction is associated with the acute effects of drugs of abuse. Abused 
substances are both rewarding and reinforcing (N. M. White, 1989). The euphoric 
response upon initial intake leads to regular use, causing a cascade of neural 
changes underlying tolerance (Nestler, 2001), and ultimately drug dependence, 
upon which cessation of drug use results in physical and psychological 
withdrawal (Evans & Cahill, 2016).  
 Drugs of abuse span diverse pharmacological categories and 
mechanisms of action; despite this there are similar states and behaviors 
associated with each stage of abuse irrespective of drug class, such as drug 
“liking” associated with the binge/intoxication stage and negative affect 
associated with the withdrawal stage (Koob & Volkow, 2010; Ozburn, Janowsky, 
& Crabbe, 2015).  
Neurobiology of Addiction 
 Even though drugs of abuse fall into diverse pharmacological categories, 
there is hypothesized to be at least some degree of convergent neurobiological 
dysfunction underlying the addictions. A common feature among drugs of abuse 
is their ability to activate the reward circuitry in the brain (Gerrits, Lesscher, & van 
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Ree, 2003). Early studies in rats identified that stimulation of specific brain 
regions was rewarding (Olds & Milner, 1954).  Subsequent studies found that 
both natural rewards and drugs of abuse require the same brain circuitry (Koob & 
Volkow, 2010; Stuber, Britt, & Bonci, 2012). Drug reward is mediated by the 
mesocorticolimbic dopamine system, which includes dopaminergic neurons in 
the ventral tegmental area (VTA), and their projections to the nucleus accumbens 
(NAc) and prefrontal cortex (Koob & Volkow, 2010). Dopaminergic mechanisms 
reinforce behaviors thought to underlie aberrant drug seeking(Bonci, Bernardi, 
Grillner, & Mercuri, 2003). A central neurobiological correlate of the reinforcing 
properties of drugs of abuse is an increase in dopamine levels in the striatum 
(Nestler, 2005), which mediates both drug-induced locomotor activity and drug 
reward (Di Chiara & Imperato, 1988; Kornetsky & Esposito, 1979) (Figure 1.1).  
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Figure 1.1: Convergent acute actions of drugs of abuse in the striatum. 
Drugs of abuse have different pharmacological profiles, but share the common 
outcome of increasing dopamine (DA) release in the striatum, which mediates 
the behavioral response to drugs of abuse. Stimulants such as 
methamphetamine (MA) directly increase synaptic dopamine in the nucleus 
accumbens (NAc) by binding to the pre-synaptic dopamine transporter as well as 
the vesicular monoamine transporters 1 and 2. Conversely, mu opioid receptor 
agonists such as oxycodone (OXY), indirectly increase dopamine, by disinhibiting 
GABA-ergic interneurons that synapse onto DAergic neurons originating in the 
ventral tegmental area (VTA). Adapted from (Nestler, 2005).  
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Mechanism of Action 
 Drugs of abuse have different pharmacological profiles, but share the 
common outcome of increasing dopamine release in the striatum (Fig. 1.1) 
(Nestler, 2005), which is integral to the rewarding effects of stimuli (Wise, 2004).  
Psychostimulants 
 Psychostimulants directly increase the extracellular concentration of 
dopamine, via three main mechanisms of action. Amphetamines, such as 
methamphetamine, are substrates for the presynaptic dopamine transporter 
(DAT), which is responsible for the re-uptake of dopamine from the synapse 
(Liang & Rutledge, 1982). By binding to DAT, amphetamines competitively inhibit 
dopamine re-uptake, thereby increasing synaptic dopamine concentration (F. J. 
White & Kalivas, 1998). Additionally, amphetamines can promote the reversal of 
DAT, leading to reverse-transport of dopamine from the cytosol into the synapse 
(Fleckenstein, Volz, Riddle, Gibb, & Hanson, 2007). In addition, amphetamines 
can promote increased dopamine release from synaptic vesicles (Bunney & 
Aghajanian, 1978) by binding to VMAT1 and VMAT2 (Fleckenstein et al., 2007).  
Opioids 
 Opioids, such as oxycodone and fentanyl, indirectly increase dopamine 
levels (Badiani, Belin, Epstein, Calu, & Shaham, 2011) (Fig.1.1). Opioids bind to 
opioid receptors, a class of 7-transmembrane G-protein coupled receptors that 
activate inhibitory G-proteins (Trescot, Datta, Lee, & Hansen, 2008). Mu, kappa, 
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and delta opioid receptors represent the originally classified receptor subtypes 
(Al-Hasani & Bruchas, 2011). The mu opioid receptor is the primary molecular 
target for the locomotor stimulant and rewarding response to opioids (Contet, 
Kieffer, & Befort, 2004; Matthes et al., 1996). Opioids are thought to induce 
reward in part by binding to mu opioid receptors on GABA-ergic interneurons in 
the VTA (Johnson & North, 1992), which disinhibits dopaminergic neurons in the 
VTA, resulting in increased dopamine release in the NAc (Nestler, 2005; Ting & 
van der Kooy, 2012) (Fig. 1.1). It is worth noting that although opioids directly 
activate mu opioid receptors, other drugs of abuse, such as cannabinoids and 
ethanol also induce the release of endogenous opioids, which in turn influence 
drug reward (Contet et al., 2004; Kieffer & Gaveriaux-Ruff, 2002). Mu opioid 
receptors can also contribute to methamphetamine-induced locomotor activity 
(Chien, Lee, Fan, Ho, & Tien, 2012) and locomotor sensitization (Tien & Ho, 
2011).  
Genetics of Addiction 
Overview 
 The majority of individuals who experiment with drugs of abuse do not go 
on to become addicted to them (Hiroi & Agatsuma, 2005). It is estimated that 
only 15-20% of individuals who engage in drug intake will become dependent 
(Degenhardt et al., 2013).  The pathogenesis of addiction is a result of a complex 
interaction between biological, social, environmental, psychological, and drug 
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use factors (Ducci & Goldman, 2012).  However, it is clear from twin, family, and 
adoption studies that there is a major genetic component in both psychostimulant 
and opioid addiction (Ducci & Goldman, 2012). Heritability estimates are 42-70% 
for psychostimulant abuse and/or dependence and 43-60% for opioid abuse 
and/or dependence (Ho et al., 2010). However, the major genetic factors remain 
unknown. 
 Recent human genome-wide association studies of opioid and 
psychostimulant use disorders have identified some promising preliminary results 
that require replication in independent cohorts as well as confirmation with larger 
sample sizes (Jensen, 2016). It is likely that hundreds of genes will be identified 
over the next decade as large consortia are formed to increase the power to 
detect genetic variants, as has recently occurred with genome-wide association 
studies of schizophrenia (Frank et al., 2015; Purcell et al., 2009). 
Disadvantages of Human Studies 
 Despite the considerable effort to investigate the genetics of addiction in 
humans, both genome-wide association and candidate gene studies have had 
limited success at identifying causal variants (Ho et al., 2010). Human genome-
wide association studies require very large sample sizes to be powered to detect 
genome-wide significant associations, which may take decades to acquire. 
Although studies may identify a gene, these frequently fail to replicate (Greene, 
Penrod, Williams, & Moore, 2009). This may be due to issues regarding power, 
chosen population, and environmental factors (Ho et al., 2010). Another issue 
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with human genetic studies is the focus on disease state rather than quantitative 
intermediate phenotypes (Donaldson & Hen, 2015). Substance use disorders are 
defined by the aggregate of symptoms that can vary across time in their 
presence and severity (Ducci & Goldman, 2012). Many of these traits are likely to 
have different genetic architectures, making it difficult to identify the underlying 
causal factors of the addicted state. Therefore, quantitative intermediate 
phenotypes may be more tractable traits for GWAS (Goldman & Ducci, 2007).  
Advantages of Mouse Models  
 Mammalian model organisms are useful for identifying novel genetic 
factors that contribute to variation in addiction-relevant intermediate phenotypes 
associated with the various stages of addiction (Palmer & de Wit, 2012). In 
particular, mice offer the most comprehensive set of genomic and molecular tools 
in mammals for identifying genes that influence complex traits (Flint & Eskin, 
2012; Mott & Flint, 2013). 
 Importantly, 99% of mouse genes have a human homologue, which 
potentially allows for translation of gene function to humans (Kile & Hilton, 2005). 
With regards to practical advantages of mouse models, it is relatively easy to 
breed and house large numbers of mice (Cryan & Holmes, 2005; Kile & Hilton, 
2005). Importantly, environmental factors can be near precisely controlled, thus 
decreasing non-genetic variance. Also, animal behavioral paradigms can 
frequently be used for high-throughput testing, allowing for rapid collection of 
phenotypes. With regards to addiction research, there is a large degree of 
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overlap in the neural circuitry and neurotransmitter systems regulating response 
to drugs of abuse in mice and humans (Edwards & Koob, 2012; Koob & Volkow, 
2010). For example, dopamine release in the striatum is a convergent 
mechanism that mediates the locomotor stimulant and reward properties of drugs 
of abuse (Adinoff, 2004; Di Chiara & Imperato, 1988). Additionally, there are 
numerous tools currently available for gene editing, which allows for the 
demonstration of causality. For example, the recent development of gene editing 
tools (i.e. CRISPRs), which permits laboratories to rapidly produce knockout or 
knock-in mouse models (Hartenian & Doench, 2015; Nemudryi, Valetdinova, 
Medvedev, & Zakian, 2014). 
 Like other neuropsychiatric disorders, it is impossible to model the 
complete complexity of addiction in mouse models due to the purely human 
nature of the disorder. However, their utility lies in the simplification of the 
disease to understand the neurobiological and genetic underpinnings of specific 
behavioral traits at various stages of the addictive process (Donaldson & Hen, 
2015; Edwards & Koob, 2012; Koob & Volkow, 2010; Palmer & de Wit, 2012; 
Schughart, Libert, & Kas, 2013) 
Drug Liking/disliking 
 Addiction is a progressive psychiatric disease and both shared as well as 
distinct genetic factors are likely to contribute to the traits accompanying the 
progressive stages of addiction (Palmer & de Wit, 2012). A common sense 
hypothesis is that those individuals who experience the most pleasure from a 
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particular drug are more prone to abuse it. In support, a retrospective survey of 
drug users found that drug “liking” was most predictive of later drug abuse across 
multiple drug classes (Haertzen, Kocher, & Miyasato, 1983). Evidence suggests 
that genetic variants contribute to subjective drug reward in non-abusing healthy 
volunteers, notably with psychostimulants such as amphetamine (Dlugos, 
Hamidovic, Palmer, & de Wit, 2009; Veenstra-VanderWeele, Qaadir, Palmer, 
Cook, & de Wit, 2006). Importantly, there is variability in the subjective response 
to opioids (Lasagna, Von Felsinger, & Beecher, 1955), including oxycodone 
(Zacny & de Wit, 2009), with some individuals “liking” the effects of the drug and 
others “disliking” the effects. 
Place Conditioning 
 Drug liking and drug disliking upon first exposure are predictive of future 
abuse (Haertzen et al., 1983). In humans, self-report is typically used to 
determine the degree of subjective drug reward. Animal models have been 
developed for many behaviors related to the different stages of addiction to 
investigate the transition from casual drug use to addiction (Ahmed, Kenny, 
Koob, & Markou, 2002). The rewarding (drug liking) or aversive (drug disliking) 
effects of drugs of abuse can be inferred using place conditioning in mammalian 
models (Koob & Volkow, 2010). Notably, place conditioning is adaptable to many 
drugs of abuse (Tzschentke, 2007), and can also be utilized in humans to assess 
abuse liability of drugs in humans (Childs & de Wit, 2009). 
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 Place conditioning is a classic Pavlovian conditioning paradigm, in which a 
drug is paired with a distinct environment. In the mouse model of place 
conditioning, a mouse is allowed to explore two different environmental contexts 
(Bardo & Bevins, 2000). During training sessions, a mouse is confined to one 
context and given drug (drug-paired) or the other context and given saline 
(saline-paired) (Fig. 1.2). Following several training sessions, the mouse will 
have access to both contexts and be tested for association of the drug with the 
drug context, with the primary measure being time spent on the drug-paired side.  
 The place conditioning paradigm can be utilized for investigating both drug 
reward (conditioned place preference, CPP) and aversion (conditioned place 
aversion, CPA) (Tzschentke, 2007). Opioid agonists, such as fentanyl and 
oxycodone (OXY) (Bryant, Guido, Kole, & Cheng, 2014; Kirkpatrick & Bryant, 
2015), produce CPP for the drug-paired side, whereas opioid antagonists, such 
as naloxone (NAL) produce CPA for the drug-paired side (Hollister, Johnson, 
Boukhabza, & Gillespie, 1981; Kirkpatrick & Bryant, 2015; Mucha & Walker, 
1987). The results of knockout mice confirm a role for the mu opioid receptor in 
both opioid agonist-induced CPP (Matthes et al., 1996) and antagonist-induced 
CPA (Skoubis, Matthes, Walwyn, Kieffer, & Maidment, 2001).   
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Figure 1.2: Place conditioning chamber and CPP/CPA behavioral paradigm.  
(A) A two-chamber design where the two sides of the chamber are differentiated 
by floor texture. The place conditioning paradigm in combination with video 
recording for automated tracking allows for the detection of numerous drug-
related behaviors, such as rotations (Rot., defined as the completion of a 
unidirectional, circular sequence across the four zones 1-2-3-4 or 3-2-1-4) or 
visits between the two sides of the chamber. (B) An example paradigm for place 
conditioning is shown. Mice are allowed access to both sides of the chamber and 
assessed for initial preference on Day 1. Days 2-5 are training days, where mice 
receive alternating injections of drug and saline prior to being confined in the 
respective compartment. On Day 6 and Day 7 mice are left undisturbed in their 
home cages for a consolidation period. On Day 8 mice are assessed for final 
preference in a drug-free state and on Day 9 mice are assessed for state-
dependent preference. Rot.= rotation, D=day, Pref.= preference, SAL=saline, 
CPP/CPA= conditioned place preference, conditioned place aversion. Adapted 
from Kirkpatrick & Bryant, 2015.  
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 NAL-CPA represents a model for the negative affective motivational 
component of opioid withdrawal (Schulteis, Markou, Gold, Stinus, & Koob, 1994 ) 
and can also be used to assess endogenous opioid tone. Agonist-naïve rodents 
and humans experience opioid antagonists such as naloxone (NAL) as dysphoric 
or aversive (Martin del Campo, McMurray, Besser, & Grossman, 1992; Mucha & 
Walker, 1987; Skoubis et al., 2001). This dysphoria is accompanied by 
physiological changes that mimic opioid withdrawal such as activation of the 
hypothalamic-pituitary-adrenal axis (Oswald, Mathena, & Wand, 2004). In 
rodents, NAL dysphoria is typically studied by treating agonist-exposed animals 
with very low doses of NAL to precipitate emotional-affective withdrawal 
symptoms, resulting in NAL avoidance/aversion of an environment paired with 
NAL (Mucha, 1987). However, because of the overlap in the architecture of 
neuronal activation in the brain following NAL administration during the agonist-
naïve (Hofford et al., 2009) and agonist-dependent state (Glass et al., 2008; 
Nakagawa et al., 2005), determining the genetic basis of NAL aversion should 
provide insight into the mechanism of the emotional-affective component of 
opioid withdrawal. Additionally, NAL-CPA can be used to assess endogenous 
opioid tone (Narayanan et al., 2004; Skoubis, Lam, Shoblock, Narayanan, & 
Maidment, 2005), that is likely relevant for the addictions and several other 
neuropsychiatric disorders, including mood disorders such as major depressive 
disorder (Jutkiewicz & Roques, 2012; Lutz & Kieffer, 2013; Slavich, Tartter, 
Brennan, & Hammen, 2014). 
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 There are numerous advantages of using the place conditioning paradigm. 
The ability to assess both reward and aversion in one paradigm is important 
because behavioral responses to drugs of abuse, including reward, follow an 
inverted U-shaped dose-response curve (Uhl, Drgonova, & Hall, 2014). A 
paradigm that evaluates both reward and aversion permits characterization of the 
full dose-response curve. Additionally, with the place conditioning paradigm, it is 
possible to analyze both drug-free and drug-dependent behaviors (Kirkpatrick & 
Bryant, 2015) (Fig. 1.2). For example, drug-induced locomotor activity and 
locomotor sensitization can be measured on training days. Primary assessment 
of CPP/CPA occurs in a drug-free state avoiding any drug-dependent changes in 
behavior. A secondary assessment of CPP/CPA can be tested under the 
influence of the drug to evaluate state-dependent reward learning. State-
dependent CPP/CPA testing evaluates the extent to which presence of the drug 
affects drug reward/aversion memory retrieval and the expression of CPP/CPA 
(Mucha & Iversen, 1984). The ability to use place conditioning to study multiple 
behavioral phenotypes associated with reward and aversion makes place 
conditioning an extremely powerful paradigm.  
Systems Genetics 
General Overview 
 Systems genetics is a powerful discovery-based approach that integrates 
intermediate phenotypes, such as gene expression, to understand the genetic 
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and biological basis of complex traits (Baliga et al., 2017; Civelek & Lusis, 2014) 
(Fig. 1.3). The goal of systems genetics analyses is to provide a multi-
dimensional framework for complex traits that integrates data from several levels 
to understand both the genetics and functional biology of complex traits at the 
holistic level (Baliga et al., 2017). 
 Forward genetics strategies, such as quantitative trait locus (QTL) 
mapping can be used to identify loci containing gene variants that are causally 
associated with variation in behavior (Tarantino & Eisener-Dorman, 2012). To fill 
in the black box between genetic variants and complex traits, intermediate 
phenotypes such as global gene expression are incorporated (Lowe & Reddy, 
2015). One method to merge genomic data with genetic variation is through 
expression QTL (eQTL) mapping, where gene expression is utilized as the 
complex quantitative trait (H. Li & Deng, 2010), and loci in linkage with genetic 
variants that are causally associated with changes in gene expression  are 
identified (Lowe & Reddy, 2015; Westra & Franke, 2014). Additional intermediate 
phenotypes such as proteomics or metabolomics can also be integrated into the 
systems genetic analysis  (Fig. 1.3B,C) (Civelek & Lusis, 2014).  
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Figure 1.3: Systems genetics approaches to complex traits. 
The goal of systems genetics is to understand the genetic, molecular, and 
neurobiological underpinnings of complex traits, by utilizing biological 
intermediate phenotypes. This figure shows systems genetics strategies of 
varying levels of complexity. (A) Global transcript levels are utilized as an 
intermediate phenotype to understand the effect of genetic perturbation on a 
behavioral trait. (B) Global transcript levels in combination with proteome and 
metabolome data are integrated to understand the effect of genetic perturbation 
on a behavioral trait. (C) Data across multiple levels (transcriptome, proteome, 
metabolome) are integrated into a biological network to model the interface of 
genetic perturbation, with the biological system to understand a behavioral trait. 
Adapted from (Civelek & Lusis, 2014) 
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Forward Genetics 
 Forward genetics strategies are unbiased, hypothesis-generating methods 
utilized to identify the relationship between genetic polymorphisms and traits (Kile 
& Hilton, 2005). Quantitative trait locus (QTL) mapping utilizes genetic and 
phenotypic variation to statistically associate a phenotype of interest with a 
region of the genome (Flint & Eskin, 2012; Phillips et al., 2002; Tarantino & 
Eisener-Dorman, 2012). QTL mapping has proved to be an extremely successful 
method for locating specific genomic regions for complex traits. Thousands of 
QTLs have been discovered in mice for diverse complex traits (Blake et al., 
2017). However, there are much fewer examples of quantitative trait genes that 
have been cloned and validated. Multiple techniques for forward genetics studies 
can be utilized; here, we will focus on the F2 intercross of two inbred strains, one 
of the most commonly used QTL mapping population (Fig. 1.4). Inbred strains, 
mouse strains that have undergone brother-sister mating for at least 20 
generations to produce genetically identical offspring (all genetic loci are fixed in 
a homozygous state) are the typical starting point of a forward genetic approach. 
Each mouse within an inbred strain is genetically identical, but extensive genetic 
and phenotypic variation exist between inbred strains (Hamilton & Frankel, 
2001). Typically, a forward genetics study begins with identification of a 
phenotypic difference between two inbred strains. The two inbred strains are 
then intercrossed to generate offspring that are heterozygous at every allele 
(F1s), and then F1s are crossed to produce the F2 generation, a segregating 
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population with offspring that are genetically distinct and equally 
related/unrelated (Phillips et al., 2002; Tarantino & Eisener-Dorman, 2012).  
 QTL mapping is a form of statistical association of genotype with 
phenotype, and as such, requires both genotypes and phenotypes. Each mouse 
must be genotyped using markers (e.g., single nucleotide polymorphisms; SNPs) 
that differentiate the two parental inbred strains (Tarantino & Eisener-Dorman, 
2012). Due to the limited recombination events in an F2 intercross, dense 
genotyping is not required (Silver, 1995). Interval mapping can be utilized to 
measure the causal association of genotypes with phenotypes. The statistical 
association of these genotypes and phenotypes results in regions of the genome 
causally associated with variation in the phenotype of interest. A logarithm of the 
odds (LOD) score indicates the strength of this statistical association between 
inheritance of a SNP marker and phenotypic variation. Identification of functional 
variants within the QTL can provide insight into potential candidate genes 
(Tarantino & Eisener-Dorman, 2012). However, a major shortcoming of QTL 
mapping is that it typically generates large genomic regions with numerous 
potential candidate genes thereby impeding the identification of the quantitative 
trait gene (QTG) (Flint & Mott, 2001). 
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Figure 1.4: Generating an F2 intercross.  
Two inbred parental strains (A, B) are bred to produce an F1 generation that is 
heterozygous at every allele. F1s are bred to generate an F2 population that 
segregates chromosomal regions containing one or two copies from each 
parental strain.  
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 Low-resolution mapping in low recombinant populations such as an F2 
cross (usually > 20 Mb, containing hundreds of genes) typically requires a 
second phase of high-resolution mapping (i.e., fine mapping), where the interval 
is slowly reduced (Kile & Hilton, 2005). Congenic and subcongenic strains are 
utilized for fine mapping (Tarantino & Eisener-Dorman, 2012) and are derived by 
repeatedly backcrossing a donor strain to a recipient strain (approximately 12 
generations), whilst retaining the donor allele in the locus of interest. The 
backcrossing is necessary to produce a congenic strain that is isogenic across 
the genome except for the QTL interval (Frankel, 1995). Fine mapping is 
achieved by the creation of a series of subcongenic mouse lines that harbor 
introgressed portions of the QTL interval (Gonzales & Palmer, 2014). Fine 
mapping requires several generations of phenotyping and genotyping while 
carefully monitoring recombination events within the QTL interval. 
 Forward genetics studies have been extremely successful at identifying 
QTLs, but have generally failed to identify specific genes (Parker & Palmer, 
2011). There are a few notable exceptions, including the identification of Mpdz as 
a quantitative trait gene for ethanol and pentobarbital withdrawal (Shirley, Walter, 
Reilly, Fehr, & Buck, 2004), and most recently in our laboratory, the identification 
of Hnrnph1 as the QTG for methamphetamine sensitivity (Yazdani et al., 2015). 
Thus, there is a continuing need for the development of new strategies to move 
more rapidly from QTL to QTG.   
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Reduced Complexity Cross 
 One potential strategy for more rapidly moving from QTL to QTG is to use 
utilize crosses with very limited genetic complexity. The C57BL/6 (B6) mouse 
strain is the most commonly used strain in biomedical research (Bryant, 2011). 
C57BL/6J (B6J) is the original B6 strain from Jackson Laboratory.  In 1951, the 
first B6 substrain (C57BL/6N) was created after breeders were shipped to the 
National Institutes of Health, which was then returned to Jackson Laboratory 
(C57BL/6NJ, B6NJ). These two closely related substrains, C57BL/6J (B6J) and 
C57BL/6NJ (B6NJ) are 99.9% genetically similar, yet exhibit significant 
differences in several addiction-associated traits (Bryant et al., 2008), including 
ethanol consumption (Mulligan et al., 2008) and psychostimulant behaviors 
(Kumar et al., 2013).  
 Typically, inbred strains possess millions of genetic variants that 
distinguish one from another. In contrast, B6J and B6NJ only possess between 
10,000 and 20,000 variants, including structural variants, SNPs, and indels 
(Keane et al., 2011; Simon et al., 2013; Yalcin et al., 2011). Whole-genome DNA 
sequencing permits the ability to map QTLs in an F2 cross of B6J and B6NJ that 
segregates a low degree of genetic diversity – referred to as the Reduced 
Complexity Cross (RCC). Accordingly, QTLs derived from the RCC contain very 
few predicted functional variants that are likely responsible for trait variation 
(Kirkpatrick et al., 2016; Kumar et al., 2013). This cross can potentially greatly 
facilitate the identification of the underlying causal genetic factors of a complex 
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trait. Although the locus identified will still be quite large (comparable to other F2 
loci), the majority of the genome can be eliminated when considering the genes 
that underlie the QTL. 
Reverse Genetics 
 Reverse genetics typically involve the introduction of a null mutation to 
determine its effect on the phenotype of interest (Argmann, Dierich, & Auwerx, 
2006). There are numerous reverse genetic tools available in mice, including 
over- or under-expression (transgenic) or complete elimination (knockout) or 
introduction of a specific variant (knock-in) (Phillips et al., 2002).  The recent 
development of rapid and efficient gene editing technologies, including 
CRIPSR/Cas9 (Clustered Regulatory Interspaced Short Palindromic Repeats), 
which can quickly and effectively generate a knockout or knockin mouse line 
using guide RNAs for Cas9 nuclease-specific digestion, can be used to directly 
demonstrate causality at the level of individual nucleotides (Hartenian & Doench, 
2015; Nemudryi et al., 2014). 
 Typically, reverse genetics is a hypothesis-drive approach. It can be 
utilized following the identification of candidate genes via QTL mapping to identify 
a quantitative trait gene (QTG) that is responsible for the phenotypic variation 
(Yazdani et al., 2015). Multiple approaches can then be used to understand the 
role of the QTG in regulating the phenotype of interest, resulting in a further 
understanding of the neurobiology of addiction relevant phenotypes. This 
information can be applied clinically for the development of novel treatments 
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(Schughart et al., 2013). Additionally, these results can be applied to humans to 
be utilized in genetic testing to prevent or predict drug abuse, or predict treatment 
success (Ho et al., 2010; Schughart et al., 2013). 
Transcriptomics 
 Natural variation and adaptive changes in gene expression are thought to 
contribute to several diseases. Gene expression is initialized by genetic and 
epigenetic factors, as well as the cellular context (Feltus, 2014). Genomic 
analysis of gene expression facilitates mechanistic hypotheses regarding the 
neurobiological mechanisms that link genetic variation with behavior. 
 QTLs for complex traits are overrepresented by variants that regulate 
gene expression (Nicolae et al., 2010). Therefore, transcriptome analysis of gene 
expression is now a mainstay complementary tool for parsing among candidate 
genes for a QTL, based on the hypothesis that differential expression of a gene 
causes the QTL. Cis-acting eQTLs containing variants that are associated with 
nearby changes in gene expression and that co-map to the same genomic region 
as behavioral QTLs can be prioritized as causal quantitative trait genes and 
provide an intermediary molecular mechanism linking genetic variation with 
behavior (Westra & Franke, 2014). Trans-acting QTLs containing genetic 
variants that are associated with distant changes in gene expression (e.g., on 
other chromosomes) and behavior can reveal gene networks that underlie 
downstream neurobiological mechanisms associated with gene expression and 
behavior. 
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 Transcriptome analysis via mRNA sequencing (RNA-seq) not only aids in 
identifying functional variants responsible for QTLs (Lionikas et al., 2012) but 
also in revealing downstream, gene networks that regulate behavior (Kirkpatrick 
et al., 2016).  
Specific Aims 
 The focus of this dissertation is investigating the genetics of addiction-
associated traits with an emphasis on the aversive and rewarding properties of 
opioids. Here, we utilized both forward and reverse genetics in combination with 
transcriptomic and bioinformatic techniques as tools to determine the molecular 
mechanisms. The two aims of this project combine forward genetics (Aim 1; 
Chapter 3) and reverse genetics (Aim 2; Chapter 2) to exhibit the utility of forward 
genetics mapping in the identification of candidate genes involved in complex 
addiction-associated traits. Delineation of the molecular signaling pathways that 
underlie the potent rewarding and/or aversive effects of drugs is necessary to 
further understand addiction, and develop treatments for this significant public 
health concern. 
 Aim 1 is to conduct a genetic linkage mapping study of addiction-
associated traits in a reduced complexity cross (RCC) using C57BL6/J (B6J) and 
C57BL6/NJ (B6NJ) mouse strains. Our lab has recently identified phenotypic 
variation in naloxone conditioned place aversion (CPA) (Kirkpatrick & Bryant, 
2015) in two substrains of a commonly used mouse strain (C57BL/6), B6J and 
B6NJ . The key advantage of the use of these substrains for genetic mapping is 
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that they are more than 99.9% genetically identical, only differing by 
approximately 10,000 single nucleotide polymorphisms (SNPs) (Simon et al., 
2013). This can potentially greatly facilitate the identification of the underlying 
causal genetic factors because the majority of the genome can be eliminated 
when considering the genes that underlie the QTL. The objective of this aim is to 
utilize the large phenotypic variation in addiction relevant traits in B6J and B6NJ 
combined with the limited genetic variation of these strains to quickly identify 
genetic factors that underlie opioid reward and aversion.  
 To accomplish this aim, we have phenotyped and genotyped 
approximately 200 mice per treatment (NAL-CPA, OXY-CPP, SAL) to identify 
significant loci mediating these behaviors. In addition, we have completed 
transcriptome analyses of striatum from a subset of OXY-treated F2 mice to 
identify eQTL and differentially expressed genes associated with differential OXY 
sensitivity (Chapter 3).  
 Aim 2 is to validate novel candidate genes and molecular mechanisms 
responsible for modulation of opioid reward and aversion. Using behavior and 
expression quantitative trait loci mapping, Csnk1e was identified as a candidate 
gene in regulating locomotor stimulant response to methamphetamine (Palmer et 
al., 2005). Because shared brain regions and neurobiological mechanisms 
mediate drug-induced locomotor activity and drug reward (Di Chiara & Imperato, 
1988; Wise & Bozarth, 1987), locomotor activity can frequently be used as a 
proxy for identifying targets that are important for the rewarding properties of 
  
32
drugs of abuse. Based on our previous study indicating a negative regulatory role 
of Csnk1e in the locomotor stimulant properties of both methamphetamine and 
fentanyl (Bryant, Graham, et al., 2009; Bryant, Parker, et al., 2012; Palmer et al., 
2005) we tested the hypothesis that Csnk1e negatively regulates the rewarding 
properties of fentanyl, methamphetamine and sweetened palatable food reward. 
Additionally, we utilized mRNA sequencing to generate novel hypotheses 
regarding the mechanism of Csnk1e in regulating drug-induced behaviors. 
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CHAPTER TWO: Casein kinase 1 epsilon deletion increases opioid 
behaviors  
Abstract  
 Genetic and pharmacological studies indicate that casein kinase-1 epsilon 
(Csnk1e) contributes to psychostimulant, opioid, and ethanol motivated 
behaviors. We previously used pharmacological inhibition to demonstrate that 
Csnk1e negatively regulates the locomotor stimulant properties of opioids and 
psychostimulants. Here, we tested the hypothesis that Csnk1e negatively 
regulates opioid and psychostimulant reward using genetic inhibition and the 
conditioned place preference assay in Csnk1e knockout mice. Similar to previous 
pharmacological studies, knockout mice showed enhanced opioid-induced 
locomotor activity with the mu opioid receptor agonist fentanyl (0.2 mg/kg i.p.). 
Furthermore, knockout mice showed enhanced sensitivity to low-dose fentanyl 
reward (0.05 mg/kg). Additionally, female knockout mice showed a markedly 
greater escalation in consumption of sweetened palatable food – a behavior 
consistent with binge eating that also depends on mu opioid receptor activation.  
In contrast, no difference was observed in fentanyl analgesia in the 52.5°C hot 
plate assay (0-0.4 mg/kg), naloxone conditioned place aversion (4 mg/kg), or 
methamphetamine conditioned place preference (0-4 mg/kg). To identify 
molecular adaptations associated with increased mu opioid-dependent reward 
behaviors in knockout mice, we completed transcriptome analysis via mRNA 
sequencing of the striatum from naïve knockout versus wild-type mice. 
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Enrichment analysis identified terms associated with myelination and axon 
guidance. Pathway analysis identified a gene set with the differentially expressed 
Wnt signaling transcription factor, Tcf7l2, regulating the expression of numerous 
genes we identified. To summarize, Csnk1e deletion increased mu opioid 
receptor-dependent behaviors, supporting previous studies indicating an 
endogenous negative regulatory role of Csnk1e in opioid behavior. 
Introduction 
 The shift from recreational to compulsive use of drugs of abuse is 
mediated by an increase in motivation to obtain drugs and a decrease in the 
rewarding properties of drugs and natural reinforcers (Adinoff, 2004; Koob & 
Volkow, 2010). Understanding the genetic and neurobiological basis of drug 
reward is central to understanding the initial neuronal adaptations underlying 
substance use disorders. Most drugs of abuse activate dopaminergic 
transmission and signaling within the striatum (Di Chiara & Imperato, 1988), a 
region of the brain that stimulates locomotor activity and drug reward learning. 
Because shared brain regions and neurobiological mechanisms mediate these 
behaviors (Di Chiara & Imperato, 1988; Wise & Bozarth, 1987), drug-induced 
locomotor activity can sometimes serve as a proxy for identifying genetic factors 
that are important for drug reward.  
 Using behavioral and expression quantitative trait locus (QTL) mapping, 
casein kinase 1 epsilon (Csnk1e) was identified as a candidate gene in 
regulating the locomotor stimulant response to methamphetamine (Palmer et al., 
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2005). Csnk1e codes for a gene from a family of serine/threonine-selective 
kinases that possess diverse biological functions and molecular substrates 
(Cheong & Virshup, 2011), including function as a clock gene in regulating 
circadian rhythms which are known to affect behavioral response to substances 
of abuse (Parekh, Ozburn, & McClung, 2015). Non-selective pharmacological 
inhibition of CSNK1E and its closely related delta isoform (CSNK1D) affect 
behaviors induced by multiple drugs of abuse, including ethanol (Perreau-Lenz et 
al., 2012), psychostimulants (Bryant, Graham, et al., 2009; Zhou et al., 2010), 
and opioids (Wager et al., 2014). A recent study used pharmacological inhibition 
of CSNK1D/E to demonstrate attenuation of reinstatement of self-administration 
of the mu-opioid receptor agonist fentanyl (Wager et al., 2014). However, it is 
unclear from reinstatement studies whether pharmacological inhibition of CK-1 
inhibits the acute rewarding or reinforcing properties of these drugs or if it has a 
selective role in disrupting stimulus-responsive neuronal adaptations underlying 
reinstatement. A further limitation of existing pharmacological studies is that the 
contribution of specific CK-1 isoforms (delta vs. epsilon) to these drug-induced 
motivated behaviors is unknown. Current evidence suggests that the delta 
isoform could normally serve to facilitate drug-induced behaviors whereas the 
epsilon isoform could normally serve to inhibit them (Bryant, Graham, et al., 
2009; Bryant, Parker, et al., 2012; Zhou et al., 2010). Pharmacological inhibition 
with the CSNK1E-preferring compound PF-4800567 increased both 
psychostimulant and opioid activity and genetic knockout of Csnk1e increased in 
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psychostimulant-induced locomotor activity (Bryant, Graham, et al., 2009; Bryant, 
Parker, et al., 2012), which indicated a negative regulatory role for the epsilon 
isoform in acute drug sensitivity. However, the effect of gene knockout of Csnk1e 
on opioid-induced locomotor activity has not been tested.  
 Based on the proposed negative regulatory role for Csnk1e in the 
locomotor stimulant properties of drugs of abuse (Bryant, Graham, et al., 2009; 
Bryant, Parker, et al., 2012), in the present study, we tested the hypothesis that 
Csnk1e negatively regulates the rewarding properties of opioids and 
psychostimulants as well as changes in the consummatory and rewarding 
behaviors induced by limited, intermittent access to sweetened palatable food 
(SPF) (Kirkpatrick et al., 2016)– a naturally rewarding stimulus. Consumption of 
highly palatable foods induces the release of endogenous opioids 
(DiFeliceantonio, Mabrouk, Kennedy, & Berridge, 2012; Nathan & Bullmore, 
2009) and dopamine that activate the mesolimbic dopamine system (Bello & 
Hajnal, 2010) and reinforce eating behavior, leading to an escalation in 
consumption. We assessed the rewarding properties of the mu opioid receptor 
agonist fentanyl and the psychostimulant methamphetamine as well as the 
escalation in consumption and rewarding properties of SPF in Csnk1e knockout 
mice as measured via conditioned place preference (CPP). To gain new insight 
into the predisposing neurobiological adaptations by which the absence of 
Csnk1e affected opioid behaviors, we used transcriptome analysis via mRNA 
sequencing (RNA-seq) of striatal tissue to identify differentially expressed genes 
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and enriched molecular pathways that were perturbed in naïve Csnk1e knockout 
versus wild-type mice. 
Materials & Methods  
Drugs  
 The mu opioid receptor agonist fentanyl citrate (FENT; Sigma-Aldrich, St. 
Louis, MO, USA), the opioid receptor antagonist naloxone hydrochloride (NAL, 
Tocris Bioscience, Bristol, UK), and the psychostimulant methamphetamine 
hydrochloride (MA, Sigma-Aldrich, St. Louis, MO, USA) were dissolved in 
sterilized physiological saline (0.9%) prior to systemic (i.p.) injection. The dose of 
FENT (0.2 mg/kg) for the locomotor experiment was chosen based on our 
previous study in C57BL/6J mice (Bryant, Parker, et al., 2012). The same dose 
was utilized in FENT-induced conditioned place preference (CPP) along with two 
additional doses (0.025, 0.05 mg/kg). The lowest dose of MA (2 mg/kg) for CPP 
was chosen based on our previous locomotor studies (Bryant, Graham, et al., 
2009; Bryant, Parker, et al., 2012). A higher MA dose (4 mg/kg) was also 
examined for MA-CPP. The dose of NAL (4 mg/kg) for NAL-CPA was chosen 
based on our recent conditioned place aversion (CPA) study in C57BL/6 mice 
(Kirkpatrick & Bryant, 2015). 
Environment and housing 
 All experiments were conducted in strict accordance with National Institute 
of Health guidelines for the Care and Use of Laboratory Animals and were 
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approved by the Boston University Institutional Animal Care and Use Committee.  
Colony rooms were maintained on a 12:12 h light–dark cycle (lights on at 0630 
h).  Mice were housed in same-sex groups of two to five mice per cage with 
standard laboratory chow (Harlan® 2918) and water available ad libitum except 
during testing.  All mice within a home cage were assigned the same treatment 
for repeated drug injection studies (CPP) or SPF-CPP. Mice were transported 
from the vivarium to the behavioral testing room next door and allowed to 
habituate for a least 1 hour prior to testing. Mice were 50-100 days old at the time 
of testing which occurred between 800 h and 1800 h.  
Mice  
 Csnk1e knockout (KO) mice were previously backcrossed to C57BL/6J for 
at least 10 generations prior to cryopreservation (Etchegaray et al., 2009). KO 
mice were generated by Cre-mediated removal of exons 2 and 3, resulting in a 
null mutation with no detectable protein product (Etchegaray et al., 2009). These 
KO mice are different from our previous study, where only exon 4 was deleted on 
a C57BL/6N background (Bryant, Parker, et al., 2012). Homozygous KO mice 
(Etchegaray et al., 2009) were re-derived using services provided by The 
Jackson Laboratory (Bar Harbor, ME, USA). Re-derived mice were further 
backcrossed to C57BL/6J mice to generate heterozygous offspring.  We then 
established a heterozygous x heterozygous breeding colony to generate 
homozygous KO and homozygous wild-type (WT) littermates for experimental 
testing. Equal numbers of age-matched KO and WT mice were tested within 
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each experimental cohort.  Genotyping was conducted on tail biopsies harvested 
at weaning via polymerase chain reaction and gel electrophoresis (Etchegaray et 
al., 2009).  
 To estimate sample size required to achieve 80% power (p < 0.05) for 
behavioral studies, we used the effect size of pharmacological inhibition of 
Csnk1e on fentanyl-induced locomotor activity (Cohens d = 1.02) (Bryant, Parker, 
et al., 2012). A sample size of 13 was required to achieve 80% power in 
detecting a genotypic effect on behavior. Therefore, our target goal for each 
behavioral study was a minimum of n=13 (mixed sexes) per Genotype per 
Treatment. Sample sizes for all experiments are listed in Table 2.1. 
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Table 2.1: Sample sizes for behavioral and transcriptomic experiments.  
Sample sizes are given for each sex, genotype, and treatment for all 
experiments. KO-F= Csnk1e knockout female, KO-M= Csnk1e knockout male, 
WT-F= wild-type female, WT-M= wild-type male; FENT= fentanyl, 
MA=methamphetamine, NAL=naloxone, SAL=saline, SPF-CPP=sweetened 
palatable food conditioned place preference. 
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Behavioral testing apparatus 
 The locomotor testing apparatus consisted of an unlit Plexiglas open field 
with Plexiglas walls (40 cm length x 20 cm width x 45 cm tall; Lafayette 
Instruments, Lafayette, IN, USA) surrounded by a sound-attenuating chamber 
(MedAssociates, St. Albans, VT, USA) (Yazdani et al., 2015). For the place 
conditioning experiments, the same unlit apparatus was partitioned into two 
equal-sized compartments via placement of a black, ion transparent, plastic 
divider containing a mouse entryway (5 cm x 6.25 cm) that was flipped upside 
down during training to confine mice to one side (Kirkpatrick & Bryant, 2015). 
Distinct floor texture squares on each side of the apparatus differentiated the two 
sides of the apparatus (Plaskolite Inc., Columbus, OH, USA).  For sweetened 
palatable food (SPF) conditioning, a small, porcelain dish was secured via 
adhesive putty to the floor texture in the far corner of each side of the chamber 
(Kirkpatrick et al., 2016). Experiments were recorded using a security camera 
system (Swann Communications, Melbourne, Australia) and the videos were 
used for tracking analysis (Anymaze, Stoelting, Wood Dale, IL, USA).  
Locomotor activity  
 We utilized a three-day locomotor protocol to assesss the acute drug 
response (Bryant, Graham, et al., 2009; Bryant, Parker, et al., 2012; Yazdani, 
Shen, Johnson, & Bryant, 2016). Prior to placement in the locomotor chamber, 
we injected mice with SAL on Day 1 (D1) and Day 2 (D2), and FENT (0.2 mg/kg, 
i.p.) or SAL (i.p.) on Day 3 (D3) and recorded activity for 30 min.  
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 We analyzed locomotor activity in 5-min time bins using mixed design 
ANOVAs. Because all mice received the same treatment on D1 and D2 (SAL), 
for these days, we collapsed across eventual Treatment assignment and used a 
two-way mixed design ANOVA (Genotype collapsed across eventual Treatment 
assignment, and Time as repeated measure), followed by post-hoc Welch’s 
unequal variance t-test.  For D3, we used a three-way mixed design ANOVA 
(Genotype, Treatment, Time as repeated measure) and pursued Genotype by 
Treatment by Time interactions using two-way ANOVAs for each Time bin 
followed by post-hoc Welch’s unequal variance t-test that was corrected for the 
number of pairwise comparisons at each Time bin (4 comparisons, FENT-WT vs. 
FENT-KO, FENT-WT vs. SAL-WT, FENT-KO vs. SAL-KO, SAL-WT vs. SAL-KO; 
p<0.05/4=0.0125).  
Place conditioning 
 We utilized an 8-day place conditioning protocol with 30-min test and 
training sessions (Kirkpatrick & Bryant, 2015). On Day 1 (D1), initial preference 
for the drug-paired side was assessed; mice received an injection of saline (SAL, 
10 ml/kg, i.p.) and were allowed free access to both sides. On training days (D2-
D5), mice received an injection of either drug (D2, D4) or SAL (D3, D5) and were 
confined to either the drug-paired or SAL-paired side, respectively. Mice were left 
undisturbed in their home cages on D6-D7. On D8, final preference for the drug-
paired side was assessed. 
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 The primary outcome measure was the difference in time spent on the 
drug-paired side between D1 and D8 (D8-D1). For each conditioning experiment, 
D8-D1 CPP/CPA we initially ran a between-subjects three-way ANOVA 
(Genotype, Dose, Sex) but because we did not observe three-way interactions 
with Sex (p > 0.05), we collapsed across sexes and used a between-subjects 
two-way ANOVA (Genotype, Dose) for D8-D1 (s) with post-hoc Welch’s t-tests 
for the effect of Genotype for each Dose. We also assessed drug-induced 
locomotor activity on D2 and D4 using between-subjects two-way ANOVA 
(Genotype, Dose).  
Baseline nociception and fentanyl analgesia 
 We used the 52.5° hot plate assay to assess baseline nociception and 
fentanyl-induced analgesia (Bryant, Roberts, Byun, Fanselow, & Evans, 2006). 
We habituated mice to the testing room for at least 1 h. We then placed mice in a 
Plexiglas cylinder (15 cm diameter; 33.0 cm tall) on a hot plate (IITC Life Science 
Inc., Woodland Hills, CA, USA) and recorded the latency to lick the hind paw with 
a 60 s cut-off latency. Thirty min post-assessment of baseline pain sensitivity, we 
injected separate mice with individual doses of FENT (0, 0.2, 0.4 mg/kg, i.p.) and 
tested them for analgesia at 10 min post-injection, which is the peak behavioral 
onset of action of FENT in C57BL/6J mice following systemic administration 
(Bryant, Roberts, et al., 2009). The experimenter was always blinded to 
Genotype at the time of behavioral assessment. We analyzed baseline latency 
via two-way ANOVA (Sex, Genotype) followed by post-hoc Welch’s t-test to 
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identify the effect of Genotype. We measured fentanyl analgesia using Percent 
Maximum Possible Effect (%MPE) (Bryant et al., 2006). We analyzed FENT 
analgesia via three-way ANOVA (Sex, Genotype, Dose), followed by a post-hoc 
two-way ANOVA with Genotype and Dose as factors.  
Sweetened palatable food place conditioning 
 We recently described a procedure for assessing sweetened palatable 
food (SPF) consumption and CPP (SPF-CPP) (Kirkpatrick et al., 2016). Briefly, 
we assessed mice for initial preference for the SPF-paired side on D1 and then 
trained mice for seven, 30 min SPF training sessions (D2, D4, D9, D11, D16, 
D18, D23) and six 30 min No SPF” training sessions (D3, D5, D10, D12, D17, 
D19). For SPF training, we confined them to the SPF-paired side with a porcelain 
dish containing 40, 20 mg 5-TUL pellets (weighted to the nearest 0.1 mg 
immediately prior to and following the session). The 5-TUL diet (TestDiet, St. 
Louis, MO USA) consists of 49.6% sucrose, and can induce an escalation in 
consumption in a mouse model of limited, intermittent access (Kirkpatrick et al., 
2016). For “No SPF training”, we confined them to the non-SPF-paired side with 
a clean, empty dish adhered to “No SPF”-paired side. To assess SPF-CPP, we 
permitted mice access to both sides of the chamber containing clean, empty food 
dishes for 30 min on D8, D15, and D22. The primary measures of interest were 
SPF consumption and SPF-CPP (D8-D1, D15-D1, D22-D1 Time on the SPF-
paired side). To account for individual and sex differences in body weight, we 
quantified SPF consumption as percent body weight. SPF consumption was 
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assessed for sex-effects with a three-way mixed design ANOVA (Sex, Genotype, 
Day as repeated measure).  Because we identified a significant two-way 
interaction of Sex and Genotype (p<0.05) for SPF-consumption, we analyzed 
SPF-consumption separately in females and males. To investigate possible 
differences in escalation in SPF intake over time, regression analyses were 
conducted in GraphPad Prism 7.01 (GraphPad Software, La Jolla, CA) as 
previously reported (Babbs, Unger, & Corwin, 2013; Kirkpatrick et al., 2016). 
SPF-CPP was first analyzed by a 3-way mixed design ANOVA (Sex, Genotype, 
Day as repeated measure), followed by analysis in both sexes separately.  
 All behavioral analyses were implemented in R (https://www.r-
project.org/).  
RNA-seq  
 We collected striatum punches from naïve female and male Csnk1e 
knockout (KO) and wild-type (WT) littermates (Table 2.1) (Kirkpatrick et al., 2016; 
Yazdani et al., 2015; Yazdani et al., 2016). We habituated mice to the dissection 
room for at least 90 min prior to sacrifice and collection of brain tissue between 
1300 h and 1700 h. Brains were rapidly removed, sectioned with a brain matrix to 
obtain a 3 mm thick section from which a 2.5 mm diameter punch of the striatum 
was collected. Pooled left and right striatum punches were immediately placed in 
RNAlater (Life Technologies, Grand Island, NY, USA) for 48 hours prior to 
storage in a -80 freezer. Total RNA was extracted (Bryant, Kole, Guido, Sokoloff, 
& Palmer, 2012) using the RNeasy kit (Qiagen, Valencia, CA, USA) and shipped 
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to the University of Chicago Genomics Core Facility where cDNA libraries were 
prepared for 50 bp single-end reads (oligo-dT) using the Illumina TruSeq® 
Stranded mRNA LT Kit (Part# RS-122-2101). Purified cDNA was captured on an 
Illumina flow cell for cluster generation and sample libraries were sequenced at 
16 samples per lane over 4 lanes (technical quadruplicates) according to the 
manufacturer’s protocols on the Illumina HiSeq 2500 machine, yielding an 
average of 38 million reads per sample. FASTQ files were quality checked via 
FASTQC and possessed Phred quality scores > 30 (i.e. less than 0.1% 
sequencing error). FASTQ files were utilized in TopHat (Kim et al., 2013) to align 
reads to the reference genome (mm10; UCSC Genome Browser). We computed 
read counts per gene using the HTSeq Python package (Anders, Pyl, & Huber, 
2015) and edgeR, a Bioconductor package for differential gene expression 
analysis that models read counts using a negative binomial distribution to 
account for variability in the number of reads via generalized linear models 
(Robinson, McCarthy, & Smyth, 2010). In order for a gene to be considered 
expressed, we required a minimum of one count per million reads (CPM) across 
all 16 samples (Yazdani et al., 2016). We included “Home Cage” (Yazdani et al., 
2016) and Sex as covariates in the statistical model to generate a list of 
differentially expressed genes (DEGs). Because of the small sample size of 
females for each genotype (n=2-3) versus males (n=4-5) (Table 2.1), we also 
included Sex as a covariate to account for variance in gene expression due to 
Sex, while at the same time increasing our power to detect differentially 
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expressed genes. Because our sample size was larger in males, we also ran a 
male-only analysis to examine concordance in the gene list between the two 
analyses. In addition, we ran a female-only analysis to generate hypotheses 
regarding female-specific changes in gene expression that may drive sex 
differences in behavior.  
 Using a standard false discovery rate (FDR) (Benjamini, Drai, Elmer, 
Kafkafi, & Golani, 2001) of 0.05, we identified a very large list of genes (2600). 
Because of our limited sample size, we were concerned that many of these 
genes could be false positives and thus, we chose to use a more stringent 
criterion of FDR = 1%. Furthermore, in examining the volcano plot, it was clear 
that the most significantly differentially expressed genes as indicated by -logP > 
20 did not begin to appear until the logFC values reached 0.15 (1.1 FC). Thus, to 
filter out presumably less reliable and less biologically relevant genes, we chose 
a minimum FC of 1.1.  
Enrichment analysis of the striatal transcriptome in Csnk1e KO mice 
 To reveal predeterminant neurobiological adaptations associated with 
behavioral differences in KO mice, we applied pathway analysis (Ingenuity 
Pathway Analysis, IPA, www.qiagen.com/ingenuity) toward our gene list to 
identify enriched biological pathways, gene networks, and upstream regulators 
(Kramer, Green, Pollard, & Tugendreich, 2014). We permitted 70 molecules 
within a gene network and restricted our analyses to mammalian species, and 
CNS tissue or cell lines. Statistical significance for enrichment was assessed 
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using a right-tailed Fisher’s exact test corrected for multiple testing (Benjamini et 
al., 2001), with a significant p-value representing an overrepresentation of 
pathway or functional procecsses. IPA analyses were run in February 2017. 
We also used Enrichr (Kuleshov et al., 2016) to rapidly compute enrichment 
scores of our gene lists for ranked terms derived from a subset of the 35 
available gene set libraries, including Gene Ontology (GO) Biological Process, 
GO Cellular Component, GO Molecular Function, and KEGG. An enrichment 
score is calculated using Fisher’s exact test along with unadjusted and adjusted 
p-values. Enrichr also corrects for this test for each “term” using several random 
input gene lists to compute a mean rank and standard deviation from the 
expected rank and provides a Z score that indicates deviation from this rank. 
Finally, using both the p-value from the Fisher’s test and this Z score, a 
“combined score”, c, is calculated as c=log(p)*Z. 
qPCR validation 
 We sought to validate our RNAseq findings in striatal tissue from a 
separate cohort of naïve KO and WT mice. Oligo-dT primers were used to 
synthesize cDNA. Each sample was run in triplicate and averaged (SD <0.5). We 
report the difference in gene expression as the change in KO relative to WT mice 
using the 2-(∆∆CT) method (Schmittgen & Livak, 2008). We analyzed gene 
expression differences of Cartpt and Csnk1e, with Hprt was as the housekeeping 
gene. We analyzed differences via unpaired Welch’s t-test, and linear regression 
with Cage as a covariate to mirror our RNAseq model.  
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Results 
Opioid-induced locomotor activity in Csnk1e knockouts  
 We previously reported that Csnk1e KOs exhibited increased MA-induced 
locomotor activity (Bryant, Parker, et al., 2012).  Here, we extended this result to 
the mu opioid receptor agonist fentanyl.  Because our primary focus was drug-
induced locomotor activity, we examined potential interactions with Sex by first 
analyzing locomotor activity on D3 using a four-way mixed design ANOVA (Sex, 
Genotype, Treatment, Time as repeated measure). For FENT-induced locomotor 
activity, we did not observe a four-way interaction or three-way interaction (Sex, 
Genotype, Treatment) (p>0.05), and thus collapsed across Sex.  
 Similar to the effect of pharmacological inhibition of CSNK1E (Bryant, 
Parker, et al., 2012), gene knockout of Csnk1e resulted in an increase locomotor 
activity on D1 and D2 (Fig. 2.1a,b).  Importantly, on D3 there was no effect of 
Genotype on locomotor activity in the SAL-treated groups at any time point 
(p>0.0125); therefore basal activity differences cannot alone account for the 
observed difference in FENT-induced locomotor activity on D3. KO mice showed 
greater FENT-induced locomotor activity (Fig. 2.1c) that mirrored the increase 
previously observed following pharmacological rather than genetic inhibition of 
CSNK1E (Bryant, Parker, et al., 2012). Although we did not reach our goal 
sample size of n=13 for the fentanyl locomotor experiment, we achieved 73% 
power with the sample size of 10-13.  
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Figure 2.1: Increased drug sensitivity in Csnk1e knockout mice.  
(A, B): A mixed design two-way ANOVA (Genotype, Time as repeated measure) 
identified a main effect of Genotype on locomotor activity on Day 1 (D1) and Day 
2 (D2) in response to SAL (F1,258=14.87, 27.99; p<0.05). Csnk1e KOs exhibited 
increased locomotor activity on D1 (t42=2.03, p<0.05) and D2 (t37=2.90, p<0.05).  
(C): A mixed-design three-way ANOVA (Genotype, Treatment, Time as repeated 
measure) on D3 identified an effect of Genotype (F1,42= 5.38, p<0.05), Treatment 
(F1,42=99.26, p<0.0001), a Genotype by Treatment interaction (F1,42=4.32, 
p<0.05), and a Time by Treatment interaction (F5, 210= 39.20, p<0.0001). To 
identify the source of the Genotype by Treatment interaction, two-way ANOVA of 
each Time bin revealed an interaction of Genotype with Treatment on Day 3 in 
response to fentanyl at 20 min post-injection (F1,42=5.05, p<0.05). Post-hoc 
Welch’s t-test corrected for four group-wise comparisons (p<0.05/4=0.0125) 
indicated that KO mice showed a trend towards greater fentanyl-induced 
locomotor activity than WT mice at 20 min (t20=2.62, p=0.0165). Importantly, 
there were no differences in locomotor activity in the SAL-treated KO and WT 
mice any time bin (p>0.0125). Data are represented as the mean ± SEM; KO= 
Csnk1e knockout, WT= wild-type, SAL= saline, FENT= fentanyl, m= meters, 
min=minutes.  
  
  
52
 
  
  
53
Drug reward in Csnk1e knockouts  
 In assessing the effect of Csnk1e deletion on FENT-CPP, there was no 
difference in baseline preference in response to saline (0 mg/kg) between 
knockouts and wild-types (t41 < 1, Fig. 2.2a). KO mice showed increased FENT-
CPP at the 0.05 mg/kg dose compared to WT mice, providing evidence for an 
increased potency of FENT reward in KO mice. We also assessed FENT-
induced locomotor activity on D2 and D4, the first and second exposure to the 
drug in our CPP paradigm. There was no main effect of Genotype (F1,210<1) or 
Genotype by Dose interaction (F3,210<1) (data not shown), indicating that the 
limited size of the CPP activity arena (which was one-half the size of the 
locomotor arena) likely affected the ability to detect effects of Csnk1e genotype 
on locomotor activity.  
  In contrast to FENT-CPP, we did not identify a difference in MA-CPP in 
Csnk1e knockouts (Fig. 2.2b). Again, as a secondary measure, we analyzed 
MA-induced locomotor activity on D2 and D4. Although there was an effect of 
Dose (D2: F2,166=19.40, D4: F2,166=20.15, p<0.05), there was no main effect of 
Genotype (F1,166<1) or Genotype by Dose Interaction(F2,166<1) (data not shown).  
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Figure 2.2: Increased opioid reward in Csnk1e knockout mice.   
(A): In examining fentanyl reward, two-way ANOVA (Genotype, Dose) identified a 
main effect of Dose (F3,210=10.37, p<0.001), and a Dose by Genotype interaction 
(F3,210=2.87, p<0.05). KO mice showed enhanced fentanyl CPP at 0.05 mg/kg (t72 
= 2.24, p<0.05). (B) A two-way ANOVA for MA-CPP identified a main effect of 
Dose (F2,166=6.64, p<0.001), but no Genotype by Dose interaction(F2,166<1). Data 
are represented as the mean ± SEM, *=p<0.05; Reward was measured via CPP 
change in time on the drug-paired side on D8 versus D1), KO= Csnk1e knockout, 
WT=wild-type, FENT= fentanyl, MA=methamphetamine, m.= meters, s.= 
seconds, i.p.=intraperitoneal.   
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 Together, these results suggest that the effect of Csnk1e deletion is more 
pronounced for opioid- versus psychostimulant-induced behaviors which is in line 
with the pharmacological results of our previous study (Bryant, Parker, et al., 
2012) and human genetic association studies of opioid versus psychostimulant 
phenotypes (Hart, de Wit, & Palmer, 2013; Levran et al., 2008; Levran et al., 
2014; Levran et al., 2015; Veenstra-VanderWeele et al., 2006). To further assess 
the role of Csnk1e in mu opioid receptor-dependent behaviors (Skoubis et al., 
2001), we assessed NAL-CPA (Kirkpatrick & Bryant, 2015; Skoubis et al., 2001). 
There was no significant effect of Genotype on NAL-CPA (t41<1 p>0.05, Fig. 2.3).  
Baseline nociception and fentanyl analgesia in Csnk1e knockouts 
 We analyzed baseline latency by two-way ANOVA (Sex, Genotype), but 
did not identify a Sex by Genotype interaction (F1,97<1), and thus collapsed 
across Sex. Although previous studies have identified a role of Csnk1e in pain 
sensitivity and mechanosensation (Sakurai et al., 2009; Young et al., 2016), we 
did not identify an effect of Genotype on baseline nociception using the hot plate 
assay (Fig. 2.4a). This suggests the role of Csnk1e in regulating pain is specific 
to the particular pain/sensory modality.  
 Three-way ANOVA (Sex, Genotype, Dose) of FENT-analgesia did not 
identify an effect of Sex (F1,89<1), or any interactions with Sex (Sex by Genotype 
F1,89<1; Sex by Dose F2,89<1; Sex by Genotype by Dose F2,89<1), and thus we 
collapsed across Sex. We did not identify a difference between Csnk1e KO and 
WT in FENT analgesia at any dose (Fig 2.4b). 
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Figure 2.3: No differences in NAL-CPA in Csnk1e knockouts.  
(A): There was no significant effect of Genotype on NAL-CPA (t41<1, p>0.05). 
Data are represented as the mean ± SEM, KO= Csnk1e knockout, WT= wild-
type, s.= seconds. 
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Figure 2.4: Baseline nociception and fentanyl analgesia in Csnk1e 
knockout mice. 
(A): In examining baseline acute thermal pain sensitivity in the hot plate assay 
(s), there was no difference between WT and KO mice (t100=-1.30, p>0.05). (B): 
For fentanyl analgesia, there was an effect of Dose (F2,138=55.49, p< 0.001) on 
percent maximum effect (% MPE), but no significant effect of Genotype (F1,138 < 
1) and no Dose by Genotype interaction (F2,138=0.816, p> 0.05). Data are 
represented as the mean ± SEM, KO= Csnk1e knockout, WT= wild-type, s.= 
seconds, % MPE= Percent Maximum Possible Effect, FENT= fentanyl, 
i.p.=intraperitoneal. 
  
  
60
 
  
  
61
SPF-CPP and consumption  
 In assessing additional mu opioid receptor-dependent behaviors, we 
examined the effect of Csnk1e deletion on the consumption and CPP for 
sweetened palatable food (SPF), a natural reinforcer. There was a significant 
Genotype by Sex interaction for both SPF consumption (Fig. 2.5a,b) and SPF-
CPP (Fig. 2.5e.f). Thus, we analyzed all subsequent phenotypes separately for 
females and males.  
 Female KOs exhibited increased SPF consumption compared to female 
WTs (Fig. 2.5 a). In stark contrast, no significant effect of Genotype was 
observed in males (Fig. 2.5b).   
 Slope analysis comparing the effect of Genotype on escalation in SPF 
intake confirmed that the effect of Csnk1e deletion on SPF consumption was 
sex-specific, with only Csnk1e KO females exhibiting escalation over time (Fig. 
2.5c, d). The lack of escalation in both female and male WTs on a C57BL/6J 
background replicates our recent study demonstrating no significant escalation in 
SPF consumption in the C57BL/6J substrain (Kirkpatrick et al., 2016).  
 To test whether sex-specific differences in body weight could account for 
increased SPF consumption in females, we analyzed body weight by two-way 
mixed model ANOVA (Genotype, Day) in females and males separately (Fig. 
2.6). There was no effect of Day in females or males which replicates our 
previous finding that this limited, intermittent access protocol for SPF does not 
result in weight gain (Kirkpatrick et al., 2016). Significant differences in body 
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weight between KOs and WTs were observed in both sexes in the same 
direction, with KO females and males weighing less than WTs at every time 
point.  Therefore, because both sexes showed similar genotypic differences in 
body weight, yet only female KOs exhibited escalation in SPF consumption, 
differences in body weight alone cannot account for the female-specific increase 
in SPF consumption in KOs.  
 For SPF-CPP in females, there was an overall effect of Genotype on SPF-
CPP across assessment days supports an increase in SPF reward that coincided 
with increased SPF consumption (Fig. 2.5e). However, for males, there was also 
an overall effect of Genotype on SPF-CPP in which male WTs showed a general 
increase in SPF-CPP in the absence of any increase in SPF consumption (Fig. 
2.5f). Thus, an increase in SPF seeking behavior was related to increased SPF 
consumption in females; however, the relationship was not straightforward in 
males. 
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Figure 2.5: Female-specific increases in SPF consumption in Csnk1e 
knockout mice.  
In examining sex differences in SPF consumption, a three-way mixed design 
(Genotype, Sex, Day as repeated measure) identified an effect of Genotype 
(F1,301=58.98, p<0.05), Sex (F1,301=75.19, p<0.05), and a Genotype by Sex 
interaction (F1,301=16.38, p<0.05). Thus, we analyzed females (A, C, E) and 
males separately (B, D, F). (A): In examining SPF consumption (% body weight) 
in females, a two-way mixed design ANOVA (Genotype, Day as repeated 
measure) revealed a main effect of Genotype (F1,105=28.65, p<0.01), but no 
effect of Day (F6,105<1) or Genotype by Day interaction (F1,105<1). Assessment of 
summed SPF consumption (% body weight) over training days revealed that 
female KO mice consumed significantly more than female WT mice (t15=3.05, 
p<0.05; inset). (B): In examining SPF consumption in males, a two-way mixed 
design ANOVA (Genotype, Day as repeated measure) revealed a main effect of 
Genotype (F1,189=4.82, p<0.05), but no effect of Day (F6,189<1) or Genotype by 
Day interaction (F1,189<1). Assessment of summed SPF consumption did not 
identify a difference between KO and WT mice (t26<1;inset). (C): Regression 
analysis of escalation in SPF consumption in females identified a significantly 
greater slope in escalation in KO mice compared to WT mice (F1,10 =9.11, p = 
0.005). (D): Conversely, in males, there was no difference between KO versus 
WT mice in the slope of SPF consumption (F1,10 <1). (E): In examining SPF-CPP 
in females, two-way mixed design ANOVA (Genotype, Subtraction Day as 
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repeated measure) identified a significant effect of Genotype (F1,45=12.67, 
p<0.05), but no effect of any particular Subtraction Day (F2,45<1, p>0.05) or 
interaction of Genotype and Subtraction Day (F2,45<1, p>0.05). Thus, there was 
an overall increase in PF-CPP in females that was in line with increased PF 
consumption. (F): In examining SPF-CPP in males, two-way mixed design 
ANOVA (Genotype, Subtraction Day as repeated measure) identified a 
significant effect of Genotype on SPF-CPP (F1,81=16.92, p<0.05), but no main 
effect of Subtraction Day (F2,81=2.21, p>0.05) or interaction of Genotype and 
Subtraction Day (F2,81<1, p>0.05). Data in A, B, E, and F are represented as the 
mean ± SEM, *=p<0.05; SPF= sweetened palatable food, % BW= represented 
as a percentage of body weight, CPP= conditioned place preference (change in 
time on the SPF-paired side relative to D1), KO= Csnk1e knockout, WT=wild-
type.  
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Figure 2.6: Body weight in SPF-CPP mice. 
(A): There was a significant effect of Genotype on body weight in females 
(F1,271=89.65, p<0.05) with WT females weighing more than KO females at every 
time point. (B): The same effect of Genotype on body weight across training days 
was observed in males (F1,475=20.68, p<0.05). Data are represented as the mean 
± SEM SPF= sweetened palatable food, D=Day, WT= wild-type, KO= Csnk1e 
knockout 
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Transcriptome analysis in striatum of Csnk1e KOs 
 To gain insight into the neurobiological adaptations underlying enhanced 
opioid behavioral sensitivity following Csnk1e deletion, we used transcriptomic 
analysis via RNA-seq of striatal tissue.  Using the standard FDR of 5%, we 
identified a very large list of genes (2600). Because of our limited sample size, 
we were concerned that many of these genes could be false positives and thus, 
we chose to use a more stringent criterion of FDR = 1%. Furthermore, in 
examining the volcano plot, it was clear that the most significantly differentially 
expressed genes as indicated by -logP > 20 did not begin to appear until the 
logFC values reached 0.15 (1.1 FC). Thus, to filter the presumably least 
biologically relevant genes, we chose a minimum fold-change of 1.1.  
 We identified 929 differentially expressed genes in KOs versus WTs (451 
upregulated, 478 downregulated DEGs; FDR <1%, fold-change > 1.1). The top 
DEG identified was Plekhb1, which exhibited a 1.19-fold increase in expression 
(p=1.44x10-73).  
 We repeated our RNAseq analysis in males only to determine the 
concordance with the larger gene list. We identified 824 differentially expressed 
genes, only 18 of which were unique. Although we were limited in our sample 
size with females, we repeated our RNA-seq analysis in females only to 
determine putative gene expression changes that may underlie sex differences in 
SPF-CPP consumption. We identified 732 differentially expressed genes. 
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Interestingly this list included only 159 genes that were on the larger gene list 
(males and females together), and 573 genes that were unique to the females. 
Pathway and enrichment analysis  
 IPA analysis identified the top network “Nervous System Development and 
Function, Neurological Disease, Organismal Injury and Abnormalities” (score = 
46, Fig. 2.7) and the second top network “Nervous System Development and 
Function, Cellular Development, Cellular Growth and Proliferation” (score=31, 
Fig. 2.8). This network includes the top upstream regulator, TCFL72, as a hub 
gene. TCFL72 was predicted to affect the expression of 53 genes in our 
differentially expressed gene list, and 31 of those genes are represented in this 
network (p-value= 7.05E-19, predicted activation; Fig. 2.8). TCF7L2 (T-cell 
Specific, HMG-Box) is a transcription factor and effector of the Wnt signaling 
pathway that regulates peptide secretion and is associated with type 2 diabetes, 
and more recently, binge eating in bipolar disorder (Cuellar-Barboza et al., 2016) 
and in our preclinical binge eating model (Kirkpatrick et al., 2016). 
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Figure 2.7: “Nervous System Development and Function, Neurological 
Disease, Organismal Injury and Abnormalities” is the top IPA network. 
 The top network includes 25 down-regulated genes (green) and 30 up-regulated 
genes (red) (Score=46). Genes in the network diagram that lack any color were 
included by the IPA algorithm to facilitate connectivity. IPA=Ingenuity Pathway 
Analysis. 
  
  
71
 
 
 
 
  
  
72
Figure 2.8: “Nervous System Development and Function, Cellular 
Development, Cellular Growth and Proliferation” IPA network includes top 
upstream regulator. 
(A, B): The 2nd top IPA network includes TCFL2, the top upstream regulator. This 
network includes 5 down-regulated genes (green) and 28 up-regulated genes 
(red) (Score=31). Genes in the network diagram that lack any color were 
included by the IPA algorithm to facilitate connectivity. IPA=Ingenuity Pathway 
Analysis, P=p-value, FC=fold-change, FDR= false discovery rate. 
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 The top molecular and cellular functions categories were: “Cellular 
Assembly and Organization” with 113 molecules (p-value= 4.94E-02 - 2.59E-12), 
“Cellular Function and Maintenance” with 114 molecules (p-value=4.94E-02 - 
2.59E-12), “Cell Morphology” with 124 molecules (p-value=4.94E-02 - 2.17E-10), 
“Cellular Development” with 127 molecules (p-value=4.94E-02 - 2.79E-10), and 
“Cellular Growth and Proliferation” with 129 molecules (p-value=4.94E-02 - 
2.79E-10). The top Physiological System Development and Function category 
was “Nervous System Development and Function” with 210 molecules (p-
value=4.94E-02 - 2.79E-10). Specifically, there was an enrichment of genes 
relevant to “differentiation of neuroglia” annotation (Predicted activation: 
increased, z-score=2.034, p-value=0.0184). Top diseases and disorders 
category was “Neurological Disease” with 189 associated molecules (p-
value=3.79E-02 - 1.71E-06). There was an enrichment of genes relevant to the 
“demyelination of nerves” annotation (Predicted activation: decreased, z-score=-
2.76, p-value= 1.71E-06).  
 The top regulator effect network was identified with Fyn and Myoc as the 
top regulators, and Cnp, Pten, Plp1, Pou3f1, and Mbp as the targets (consistency 
score=2.683, Fig. 2.9). Differential expression of these targets was included in 
the diseases and function annotations  “differentiation of neuroglia” 
“hypomyelination”, specifically by decreasing hypomyelination and increasing 
differentiation of neuroglia.  
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Figure 2.9: Top regulator effect network predicts increased differentiation 
of neuroglia and decreased hypomyelination. 
(A, B): Regulator effect networks link upstream regulators with downstream gene 
expression changes, and hypothesized phenotypic effects. Upstream regulators, 
FYC and MYOC, affect the expression of 5 genes (CNP, PTEN, PLP1, POU3F1, 
MBP) which lead to increased differentiation of neuroglia and decreased 
hypomyelination. P=p-value, FC=fold-change, FDR= false discovery rate. 
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 Complementary to the IPA results, enrichment analysis using Enrichr 
(Kuleshov et al., 2016) provided further evidence for a role in myelination and 
axon guidance (Table 2.2). It identified “ensheathment of neurons”, “myelination”, 
and “axon ensheathment” as 3 of the top GO biological processes. A top term for 
GO cellular component was myelin sheath, identifying six genes that are 
enriched in the myelin sheath. In additional, MGI Mammalian Phenotype level 4 
identified 20 genes that were related to the term “abnormal myelination” and 28 
genes related to “abnormal glial cell” (Table 2.2). One of the top KEGG, GO 
molecular processes, and Reactome terms identified was “Axon guidance”. In 
addition, “semaphorin receptor activity” was identified as a top GO molecular 
function annotation and “NCAM signaling for neurite growth” was identified as a 
top Reactome term (Table 2.2).  
 In addition, we completed enrichment analysis in the 573 genes that were 
unique to the females only RNAseq analysis (Table 2.3). Despite a very different 
gene list, similar enrichment terms were identified. Top GO biological process 
term was “axon guidance”, “nervous system development”, and “glycerolipid 
biosynthetic process”. Top mammalian phenotype terms included “abnormal glial 
cell” and “abnormal myelination” (Table 2.3).  
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Table 2.2: Enrichment analysis of the striatal transcriptome of Csnk1e KO 
mice. 
The top five enrichment terms or those terms reaching an adjusted P (Adj.P) of 
less than 0.05 are shown for various ontology databases powered by the online 
Enrichr tool (http://amp.pharm.mssm.edu/Enrichr/; Kuleshov et al. 2016). 
Csnk1e= Casein kinase 1 epsilon, KO= knockout, KEGG= Kyoto Encyclopedia of 
Genes and Genomes, GO= Gene Ontology, Bio.= Biological, Comp.= 
Component, Molec.= Molecular, MGI Mam. Pheno. 4= Mouse Genome 
Informatics Mammalian Phenotype Level 4, PPI= Protein-protein Interaction 
Network. 
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Table 2.3: Enrichment analysis of the striatal transcriptome of female 
Csnk1e KO mice. 
The top five enrichment terms or those terms reaching an adjusted P (Adj.P) of 
less than 0.05 are shown for various ontology databases powered by the online 
Enrichr tool (http://amp.pharm.mssm.edu/Enrichr/; Kuleshov et al. 2016).  This 
table differs from Table 2.2 in that it only includes female KO and WT mice. 
Csnk1e= Casein kinase 1 epsilon, KO= knockout, KEGG= Kyoto Encyclopedia of 
Genes and Genomes, GO= Gene Ontology, Bio.= Biological, Comp.= 
Component, Molec.= Molecular, MGI Mam. Pheno. 4= Mouse Genome 
Informatics Mammalian Phenotype Level 4, PPI= Protein-protein Interaction 
Network. 
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qPCR validation in striatum of Csnk1e KOs 
 We sought to validate our RNAseq findings in an additional cohort of naïve 
Csnk1e KOs and WTs (Table 2.1). We did not have enough female samples 
available to include in the analysis (n=1-2); therefore, we used only male 
samples (n=4-5/genotype). We identified a significant difference in expression of 
Cartpt in the additional cohort (p<0.05; Table 2.4). As a positive control, we 
assessed expression of Csnk1e using primers that targeted the 2 deleted exons 
in the KO (exons 2-3) to confirm that KOs expressed the gene lacking these 2 
exons. 
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Table 2.4: qPCR results for mRNA-seq validation. 
qPCR results were analyzed via unpaired Welch’s t-test and ANCOVA without or 
with cage as a covariate. Statistic (t or F), degrees of freedom (D.F.), and p-value 
are listed for both statistical analyses. The targeted region, forward and reverse 
primer sequences are listed. 
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Discussion  
 We and others previously identified a role of Csnk1e in regulating the 
behavioral response to multiple drugs of abuse, including ethanol (Perreau-Lenz 
et al., 2012), opioids (Bryant, Parker, et al., 2012; Wager et al., 2014), and 
psychostimulants (Bryant, Graham, et al., 2009; Bryant, Parker, et al., 2012; 
Palmer et al., 2005; Zhou et al., 2010).  Here, we extended the enhanced 
locomotor stimulant response to psychostimulants following Csnk1e deletion to 
include enhanced sensitivity to opioid-induced locomotor activity and opioid 
reward (Fig. 2.1c, 2.2a). In support of our previous study (Bryant, Parker, et al., 
2012), the effect of Csnk1e deletion was more pronounced for opioid behavior 
(Fig.2.1c, 2.2a). Genetic association studies of human CSNK1E polymorphisms 
reported an association of a CSNK1E SNP (rs135745) with amphetamine 
euphoria in humans (Veenstra-VanderWeele et al., 2006) that failed to replicate 
(Hart et al., 2013). In contrast, an association of the CSNK1E SNP rs5757037, 
with heroin dependence was replicated in two populations (Levran et al., 2008; 
Levran et al., 2014; Levran et al., 2015). Thus, multiple lines of evidence in mice 
and humans indicate the importance of Csnk1e in opioid behaviors.   
 Interestingly, we also found that Csnk1e induced a female-specific 
escalation in SPF consumption in Csnk1e KO mice (Fig 2.5). Escalation in SPF 
consumption has also been shown to depend on endogenous striatal mu opioid 
receptor signaling (DiFeliceantonio et al., 2012; Nathan & Bullmore, 2009). 
(Giuliano & Cottone, 2015).  Opioid receptor antagonists can also attenuate 
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conditioned place preference for a palatable food-paired environment (Jarosz, 
Sekhon, & Coscina, 2006).  
 To identify molecular adaptations associated with increased mu opioid-
dependent reward behaviors in knockout mice, we completed transcriptome 
analysis via mRNA sequencing of the striatum from naïve knockout versus wild-
type mice. Enrichment analysis identified an enrichment of genes relevant to 
myelination and axonal guidance (Table 2.2). Together, this emphasizes 
neurodevelopment differences induced by Csnk1e deletion as a predisposing 
neurobiological condition. Pathway analysis also pointed to a noteworthy role of 
Wnt signaling, with Tcf7l2 as a Wnt singaling effector and GSK3B identified as a 
top PPI hub protein (Table 2.2). Csnk1e is a positive regulator of the Wnt 
signaling pathway (Sakanaka, Leong, Xu, Harrison, & Williams, 1999), by 
phosphorylating substrates such as disheveled, axin, and Tcf-3 (Cheong & 
Virshup, 2011; Yim & Virshup, 2013).  
 Tcf7l2, a transcription factor necessary for oligodendrocyte differentiation 
(Zhao et al., 2016) was identified as a top upstream regulator (Fig. 2.8). There is 
a growing appreciation for the importance of glia cells and more specifically 
myelin-producing oligodendrocytes in the neurobiology of addiction (Miguel-
Hidalgo, 2009). White matter defects are associated with numerous 
neuropsychiatric disorders and conversely, alterations in oligodendocryte 
signaling can affect dopaminergic function and psychostimulant-induced 
locomotor activity (Roy et al., 2007).  
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 An important limitation of our transcriptome findings is the smaller sample 
size of the females. Although we have provided gene expression analyses in the 
female mice, we understand that with a sample size of 2-3 per genotype, these 
results are putative and should be followed by a comprehensive analysis in 
female Csnk1e knockouts.  Our previous study did not identify Csnk1e Genotype 
by Sex interactions in drug-induced behaviors (Bryant, Parker, et al., 2012) and 
thus, when we first planned these studies several years ago, we did not explicitly 
design the experiments with the intention of testing for Genotype by Sex 
interactions. Our results, especially in light of the relatively recent emphasis of 
the National Institutes of Health on the inclusion of Sex as a biological variable 
(Miller et al., 2017) underscores the need for future studies regarding Csnk1e in 
gene expression and behavior to be powered to detect Genotype by Sex 
interactions. The sex-specific effect of Csnk1e deletion on escalation in SPF 
consumption was particularly surprising and warrants a future comprehensive 
investigation involving multiple brain regions and additional variables (e.g., estrus 
cycle) to address female-specific mechanisms. 
 Our findings provide increasing support for Csnk1e in negatively 
regulating mu opioid receptor-dependent behaviors that are relevant to 
substance abuse and enriched biological pathways that could bridge Csnk1e 
genotype with behavior. Previous studies have focused primarily on dopamine 
signaling molecules, including dopamine- and cAMP-regulated phosphoprotein-
32 kDa (DARPP-32), in mediating CK-1 effects on drug behaviors (Bryant, 
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Graham, et al., 2009; Levran et al., 2014; D. Li et al., 2011; Palmer et al., 2005). 
Our study has uncovered that baseline differences in neuronal development and 
myelination that may underlie mechanisms by which Csnk1e deletion affects the 
response to abused substances.  
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CHAPTER THREE: Systems genetic analysis and fine mapping in a reduced 
complexity cross rapidly leads to the identification of compelling candidate 
genes underlying behavioral addiction traits 
Abstract 
 Opioid addiction is a heritable substance use disorder with an unknown 
genetic etiology. The use of mammalian model organisms permit a 
comprehensive approach to forward genetics in bridging genetic variation with 
neurobiological mechanisms of addiction-relevant behaviors, including acute 
sensitivity to psychomotor stimulation, reward, and aversion. The closely related 
C57BL/6J and C57BL/6NJ substrains show extremely limited genetic diversity, 
yet show differences in alcohol consumption, binge eating, psychostimulant-
induced locomotor activity, and aversion in response to blockade of endogenous 
opioids. Here, we replicated strain differences in methamphetamine-induced 
locomotor activity and used quantitative trait locus (QTL) mapping to identify a 
QTL on chromosome 5 (LOD=3.9, 52-99 Mb) that co-mapped with a striatal cis-
expression QTL (eQTL) for Gabra2 (71 Mb). Next, we mapped QTLs for opioid-
induced locomotor activity and withdrawal induced by the mu opioid receptor 
agonist oxycodone to distal chromosome 1 (LOD=4.7-9.8; 152-181 Mb). We 
backcrossed recombinant F2 mice based on this QTL genotype to C57BL/6J and 
fine mapped a region containing a well-known neurobehavioral QTL ‘hotspot” 
(chr1: 172-178 Mb). Shared haplotype analysis of C57BL/6NJ and classical 
inbred strains combined with cis-eQTL analysis of F2 mice identified three strong 
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positional candidate genes for oxycodone behaviors - Cadm3, Aim2, and Rgs7. 
Pathway analysis in opioid withdrawn F2 mice identified two major hub genes - 
Mapt and App. Finally, we identified a major QTL for naloxone-induced aversion-
associated freezing behavior on chromosome 18 (LOD=6.2; 35-62 Mb) that 
mapped near a striatal cis-eQTL for Onecut2 (64 Mb), a gene involved in 
neurodevelopment of the locus coeruleus. To summarize, systems genetic and 
fine mapping analysis in a reduced complexity cross of C57BL/6J and 
C57BL/6NJ revealed multiple candidate genes underlying addiction traits. 
Introduction 
  Abuse of opioids, including the prescription opioid oxycodone and more 
recently, heroin, has reached epidemic levels in the United States (Oderda et al., 
2015; Rudd, Seth, David, & Scholl, 2016). Opioid addiction is a devastating 
neuropsychiatric disorder in which casual use transitions to regular and 
compulsive use (Kalivas & O'Brien, 2008; Piazza & Deroche-Gamonet, 2013).  
Despite the extraordinarily high abuse potential of opioids, the vast majority of 
individuals who have tried opioids do not transition to addiction (Hiroi & 
Agatsuma, 2005). The shift from casual use to addiction occurs as a result of a 
complex interaction of both genetic and environmental factors (Ho et al., 2010). 
Twin studies estimate that opioid abuse is 43-60% heritable (Ducci & Goldman, 
2012; Ho et al., 2010). Currently, the genetic basis of opioid addiction and other 
substance use disorders remain poorly understood (Ho et al., 2010; Jensen, 
2016).  
  
91
 Individual genetic factors likely contribute to the different stages and 
behaviors of addiction (Palmer & de Wit, 2012), including initial sensitivity to the 
subjective and physiological effects of drugs and physiological and psychological 
measures of withdrawal. One way to potentially reduce genetic complexity is to 
focus on clearly heritable intermediate phenotypes that predict disease state, 
including behavior and gene expression (Glahn et al., 2014). Humans vary in 
their subjective response to opioids (Lasagna et al., 1955; Zacny & de Wit, 
2009), with some people reporting a rewarding experience and others reporting 
an aversive one. Importantly, drug “liking” can predict later opioid abuse 
(Haertzen et al., 1983). An overarching hypothesis is that the genetic component 
of opioid sensitivity (“liking” vs. “disliking”) may influence risk for developing 
opioid addiction. This rewarding (drug liking) or aversive (drug disliking) 
component of drugs of abuse can be studied in mammalian model organisms 
using place conditioning (Bardo & Bevins, 2000; Koob & Volkow, 2010; 
Tzschentke, 2007), a behavioral paradigm that is adaptable to many species, 
including humans (Childs & de Wit, 2009) and several drugs of abuse 
(Tzschentke, 2007). In addition, concomitant sensitivity to drug-induced 
locomotor activity can be measured during training, which can sometimes predict 
drug reward and reinforcement. Opioid agonists, such as oxycodone (OXY), 
produce conditioned place preference (CPP) for the drug-paired environment 
(Bryant et al., 2014; Kirkpatrick & Bryant, 2015). In contrast, mu opioid receptor 
antagonists induce conditioned place aversion (CPA) for the drug-paired 
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environment (Mucha, 1987; Skoubis et al., 2005; Skoubis et al., 2001) and 
induce dysphoria in humans (Hollister et al., 1981). CPA induced by mu opioid 
receptor antagonists such as naloxone (NAL; NAL-CPA) can model the negative 
affective-motivational component of opioid withdrawal (Schulteis et al., 1994) and 
the contribution of endogenous opioid tone to basal emotional-affective state 
(Narayanan et al., 2004; Skoubis et al., 2005), that likely influences the 
addictions and other neuropsychiatric disorders, such as depression (Jutkiewicz 
& Roques, 2012; Lutz & Kieffer, 2013; Slavich et al., 2014).  
Mice are a valuable mammalian model organism in forward genetics for 
identifying novel genes that contribute to variation in addiction-relevant traits 
(Kirkpatrick et al., 2016; Kumar et al., 2013; Shirley et al., 2004; Yazdani et al., 
2015). Approximately 99% of mouse genes have a human homolog (Guenet, 
2005), allowing for translation of findings from mouse to human (Palmer & de 
Wit, 2012). Importantly there is a large degree of overlap in the neural circuitry 
and neurotransmitter systems regulating response to drugs of abuse in mice and 
humans (Edwards & Koob, 2012; Koob & Volkow, 2010). For example, dopamine 
release in the striatum is a convergent neurobiological event that is associated 
with both the locomotor stimulant and reward properties of drugs of abuse 
(Adinoff, 2004; Di Chiara & Imperato, 1988).  
 The C57BL/6 (B6) mouse strain is the most commonly used strain in 
biomedical research (Bryant, 2011). Two closely related substrains, C57BL/6J 
(B6J) and C57BL/6NJ (B6NJ) are 99.9% genetically similar, yet exhibit significant 
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differences in several addiction-associated traits (Bryant et al., 2008), including 
ethanol consumption (Mulligan et al., 2008), psychostimulant behaviors (Kumar 
et al., 2013), NAL-CPA (Kirkpatrick & Bryant, 2015), and binge eating (Kirkpatrick 
et al., 2016). Although phenotypic differences between B6 substrains can be 
quite large (Kirkpatrick & Bryant, 2015; Kirkpatrick et al., 2016; Simon et al., 
2013), genotypic diversity is extremely small, with only 10,000 to 20,000 variants 
distinguishing the two strains as opposed to 4 to 35 million variants distinguishing 
the reference B6J strain from other classical inbred strains (Keane et al., 2011; 
Simon et al., 2013; Yalcin et al., 2011).  
 We recently found a robust difference in NAL-CPA between B6J and 
B6NJ, with B6J exhibiting a three-fold increase (Kirkpatrick & Bryant, 2015). 
Factor analysis identified additional behaviors that were highly correlated with 
increased NAL-CPA in B6J mice, including an increase in the number of freezing 
episodes. Sensitivity to NAL-CPA is frequently assessed during the opioid-
dependent state as a measure of negative emotional-affective withdrawal that 
can drive continued drug seeking (Azar, Jones, & Schulteis, 2003). Phenotypic 
differences between inbred strains implicate an underlying genetic basis 
(Cunningham, Niehus, Malott, & Prather, 1992) and thus, identifying the genetic 
basis of sensitivity to NAL-CPA could identify genes relevant for opioid 
withdrawal.  
Systems genetics is a powerful discovery-based approach that integrates 
multiple intermediate genomic measures, to investigate the genetic and biological 
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basis of complex traits (Baliga et al., 2017; Civelek & Lusis, 2014). Forward 
genetics, including quantitative trait locus (QTL) mapping can be used to identify 
loci containing gene variants that are causally associated with variation in 
behavior (Tarantino & Eisener-Dorman, 2012). Furthermore, complementary 
expression QTL (eQTL) mapping can be used to identify loci causally associated 
with variation in gene expression (Lowe & Reddy, 2015; Westra & Franke, 2014). 
Cis-acting eQTLs (cis-eQTLs) containing variants that are associated with nearby 
changes in gene expression and that co-map to the same genomic region as 
behavioral QTLs can be prioritized as causal quantitative trait genes and provide 
an intermediary molecular mechanism linking genetic variation with behavior 
(Lowe & Reddy, 2015). Trans-acting QTLs containing genetic variants that are 
associated with distant changes in gene expression (e.g., on other 
chromosomes) and behavior can reveal gene networks that comprise 
downstream neurobiological mechanisms of behavior (Mott & Flint, 2013). Third, 
transcriptome analysis of global changes in gene expression that are associated 
with a particular behavioral QTL can also aid in informing neurobiological 
mechanisms of behavioral addiction traits (Kirkpatrick et al., 2016; Lionikas et al., 
2012). 
The goal of the present study was to apply a systems genetic approach in 
a cross between closely related B6 substrains (the reduced complexity cross, 
RCC) (Williams & Williams, 2017) to rapidly identify high priority candidate genes 
underlying variation in several behavioral addiction traits. An important 
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advantage of the RCC is that while the QTLs identified are quite large in size 
(tens of Mb), the number of genetic variants underlying these QTLs is orders of 
magnitude lower (Kirkpatrick et al., 2016; Kumar et al., 2013). We and others 
have used this cross to rapidly identify Cyfip2 as a major genetic factor 
underlying addiction traits (Kirkpatrick et al., 2016; Kumar et al., 2013).  
In this study, we conducted a systems genetic analysis of locomotor 
stimulant and/or conditioned motivational behaviors (reward and aversion) 
induced by three drugs: the psychostimulant methamphetamine (MA), the mu 
opioid receptor agonist oxycodone (OXY), and the mu opioid receptor antagonist 
naloxone (NAL).  We also focused on the emotional-affective component of 
opioid withdrawal in oxycodone-dependent mice using the elevated plus maze 
(Buckman, Hodgson, Hofford, & Eitan, 2009; Hodgson, Hofford, Norris, & Eitan, 
2008; Hofford et al., 2009). Finally, we mapped the genetic basis of B6 substrain 
differences in baseline acute pain sensitivity on the hot plate (Bryant et al., 2008). 
 We chose to fine map a QTL for OXY behavioral sensitivity - a Mendelian 
trait - via backcrossing a subset of recombinant F2 mice within the QTL interval. 
The assumption was that Mendelian traits on a nearly isogenic background can 
be immediately fine mapped without the usual requirement of greater than 10 
generations of backcrossing due to the pre-exisiting near-isogenic background in 
F2 mice and the low risk for epistatic interactions interfering with QTL detection. 
In addition to behavioral QTL analysis, we conducted transcriptome analysis of 
the striatum, a major brain region important for the locomotor stimulant properties 
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of drugs of abuse, in a subset of OXY-treated F2 mice. We conducted two 
complementary transcriptome analyses. First, to prioritize candidate genes 
underlying behavioral QTLs, we identified cis-eQTLs that were associated with 
both gene expression and the location of the behavioral QTLs. Second, because 
we identified a major QTL on distal chromosome 1 that was associated with 
behavioral sensitivity to OXY, we conducted transcriptome analysis of 
differentially expressed genes as a function of genotype within this QTL in opioid-
withdrawn mice that revealed genomic changes in gene expression as a function 
of this locus that were associated with opioid sensitivity and withdrawal . Our 
comprehensive systems genetic analysis of addiction traits in a reduced 
complexity genetic cross has identified multiple compelling candidate QTL genes 
and downstream networks that await validation.  
 
Materials & Methods 
Drugs 
 Oxycodone hydrochloride (OXY, Sigma-Aldrich, St. Louis, MO, USA), 
naloxone hydrochloride (NAL, Tocris Bioscience, Bristol, UK), and 
methamphetamine (MA) were dissolved in sterilized physiological saline (0.9%) 
prior to systemic (i.p.) injections. The dose of OXY for CPP (1.25 mg/kg), hot 
plate testing (5 mg/kg), and chronic injections (20 mg/kg) were chosen based on 
preliminary studies in B6J and B6NJ. The dose of MA (2 mg/kg) for the locomotor 
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activity assay was chosen based on preliminary studies in B6J and B6NJ. The 
dose of NAL (4 mg/kg) was chosen based on our previous study where this dose 
induced significant differences in CPA between B6J and B6NJ (Kirkpatrick & 
Bryant, 2015).  
Environment and Housing 
 All experiments were conducted in strict accordance with National Institute 
of Health guidelines for the Care and Use of Laboratory Animals and approved 
by the Boston University Institutional Animal Care and Use Committee. Colony 
rooms were maintained on a 12:12 h light–dark cycle (lights on at 0630 h). Mice 
were housed in same-sex groups of two to five mice per cage with standard 
laboratory chow and water available ad libitum except during testing. Mice were 
50-100 days old at the time of testing. 
Mice 
 C57BL/6J (B6J) and C57BL/NJ (B6NJ) mice were purchased from The 
Jackson Laboratory (Bar Harbor, ME) at 7 weeks of age and were habituated in 
the vivarium one week prior to experimental testing that occurred next door. All 
behavioral testing was performed during the light phase of the 12 h light/dark 
cycle (0800 h to 1300 h). For QTL mapping, B6J females were crossed to B6NJ 
males to generate B6J x B6NJ-F1 mice and then B6J x B6NJ F1 offspring were 
intercrossed to generate B6J x B6NJ F2s. All mice within a cage receive the 
same treatment.  
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 To estimate sample size of F2 mice required to achieve 80% power (p < 
0.05) for QTL mapping, we utilized the results from our recent study using the 
same cross to identify Cyfip2 as a genetic regulator of palatable food 
consumption (Kirkpatrick et al., 2016). Based on an effect size Cohen’s d = 1.23 
(N=32-33 homozygous B6J and homozygous B6NJ at the Cyfip2 locus; 150 F2 
mice total) we achieved 99.8% power to detect a significant difference (p < 0.05, 
two-tailed test). Only 12 J and 12 NJ mice would have been required to achieve 
80% power. If we assume a more conservative, medium effect size QTL (d = 0.6) 
with 80% power (p < 0.05), a sample size of 46 J and 44 NJ mice. If we assume 
a 1:2:1 Mendelian ratio for the F2 offspring, approximately N=180 F2 mice need to 
be phenotyped. Therefore, to ensure sufficient power, we aimed to use a sample 
size of at least 200 per treatment group (NAL-CPA, OXY-CPP, SAL).  
Recombinant-F2 mice 
 We took advantage of the nearly isogenic background of the RCC F2 
offspring and devised a rapid approach for fine mapping. We selected F2 mice 
based on genotypes at distal chromosome 1 (from the SNP array; 163 Mb, 181 
Mb) to backcross to B6J to generate mice that were either homozygous B6J (J/J) 
or heterozygous (J/N) across distal chromosome 1. Based on the observation 
that Day 2 OXY-induced locomotor activity was a Mendelian trait and therefore, 
unlikely to be influenced by background alleles elsewhere in the genome, we 
disregarded genotype elsewhere in the genome, and focused solely on 
recombination events at distal chromosome 1 (163-190 Mb).  
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 To estimate sample size of F2 recombinants required to achieve 80% 
power (p < 0.05) for fine mapping, we utilized the mean and standard deviations 
of OXY-induced locomotor activity based on genotype at the peak marker on 
chromosome 1 (rs51237371, J/J vs. J/N). Based on an effect size Cohen’s d= 
0.79 (N=59 J/J, N=105 J/N; 206 F2 mice total), we achieved 99.9% power to 
detect a significant difference (p < 0.05, two-tailed test). Based on this effect size, 
only 27 homozygous J/J and 27 heterozygous J/N mice are required to achieve 
80% power (2-tailed test, p <0.05). Therefore, we aimed to use a sample size of 
at least 27 mice per F2 recombinant strain.  
Behavioral Testing  
Pipeline: 
 F2 mice were tested for multiple addiction-associated phenotypes. Weeks 
1 and 2 consisted of place conditioning (OXY-CPP n=212, NAL-CPA n=209, 
SAL=213). For a subset of NAL-trained mice (n=184), Week 3 consisted of 
methamphetamine locomotor activity testing. For a subset of SAL- and OXY- 
treated mice, Week 3 consisted of once daily injections of either saline (SAL 
group), or oxycodone (20 mg/kg, i.p.; OXY group) for four days and oxycodone 
analgesia testing on the fifth day for both groups (5 mg/kg, i.p. OXY n=81, SAL 
n= 83, total n=164). Week 4 consisted of once daily injections of either OXY (20 
mg/kg, i.p.; OXY group) or SAL (i.p.; SAL group) for four days and elevated plus 
maze testing 16-24 h later (OXY n= 118, SAL n=118).  
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Apparatus 
 The locomotor activity apparatus consisted of an open field (40 cm length 
x 20 cm width x 45 cm tall; Lafayette Instruments, Lafayette, IN, USA) that was 
employed for MA locomotor studies surrounded by a sound-attenuating chamber 
(MedAssociates, St. Albans, VT, USA). For place conditioning, we partitioned the 
apparatus into two equal-sized compartments via placement of an ion 
transparent plastic black divider containing a mouse entryway (5 cm x 6.25 cm) 
that was flipped upside down during training to confine mice to one side. We 
used distinct floor textures squares on each side differentiate them (Plaskolite 
Inc., Columbus, OH, USA). Behavioral data were recorded using a security 
camera system (Swann Communications, Melbourne, Australia) and subjected to 
video tracking analysis (Anymaze, Stoelting, Wood Dale, IL, USA).  
Place Conditioning 
 The conditioned place preference (CPP)/conditioned place aversion (CPA) 
procedure was recently described (Kirkpatrick & Bryant, 2015). Briefly, we 
utilized a 9-day protocol with 30-min test and training sessions; all injections 
occurred immediately prior to placement in the testing apparatus. On Day 1 (D1), 
initial preference for the drug-paired side was assessed; mice received an 
injection of saline (SAL, 10 ml/kg, i.p.) and allowed free access to both sides. On 
training days (D2-D5), mice received an injection of either drug (D2, D4) or SAL 
(D3, D5) and were confined to either the drug-paired or SAL-paired side, 
respectively. Mice were left undisturbed in their home cages on D6 and D7. On 
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D8, drug-free conditioned preference/aversion for the drug-paired side was 
assessed, as on D1. On D9, state-dependent preference/aversion for the drug-
paired side was similarly assessed, except that it was assessed under the 
influence of the drug (same dose as training dose). Mice were then left 
undisturbed in their home cages for the rest of Week 2.   
 We utilized this procedure to assess OXY-CPP (OXY, 1.25 mg/kg) and 
NAL-CPA (NAL, 4 mg/kg) (Kirkpatrick & Bryant, 2015) versus SAL-treated mice 
receiving saline injections (10 ml/kg, i.p.) on all training and testing days. Our 
main outcome measures included the difference in time spent on the drug-paired 
side between D1 and D8 or D9 (D8-D1, D9-D1) and locomotor activity (D2, D4). 
We examined other behaviors (e.g., rotations, freezing, spins) based on factor 
analysis of OXY and NAL behaviors (Kirkpatrick & Bryant, 2015).  
 For recombinant F2 mice, we focused on fine mapping D2 OXY-induced 
locomotor activity and thus, used an abbreviated two day version of our place 
conditioned paradigm (D1 included SAL open access, D2 included injection of 
1.25 mg/kg OXY and confined to the OXY-paired side).  
Baseline nociception and OXY analgesia 
 For Week 3, we injected mice once daily with SAL or OXY (20 mg/kg, i.p.) 
on Days 1-4 in order to induce tolerance. On Day 5, we tested mice for baseline 
pain sensitivity in the 52.5ºC hot plate assay to assess baseline nociception and 
OXY-induced analgesia (Bryant et al., 2006). We habituated mice to the testing 
room for at least 1 h. We then placed mice in a Plexiglas cylinder (15 cm 
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diameter; 33.0 cm tall) on a hot plate (IITC Life Science Inc., Woodland Hills, CA, 
USA) and recorded the latency to lick the hind paw with a 60 s cut-off latency. 
Thirty min post-assessment of baseline pain sensitivity, we injected mice with 
OXY (5 mg/kg, i.p.) and tested them for analgesia at 30 min post-injection, which 
is the peak time point of analgesic effect of OXY in mice (Bhalla, Ali, Lee, 
Andurkar, & Gulati, 2013). Mice were left undisturbed in their home cages for 
Days 6 and 7 of Week 3.  
 Elevated plus maze 
 For Week 4, we injected mice once daily with SAL or OXY (20 mg/kg, i.p.) 
on Days 1-4 in order to induce dependence. On Day 5, mice were tested for the 
emotional-affective component of spontaneous opioid withdrawal (Schulteis, 
Yackey, Risbrough, & Koob, 1998) using the elevated plus maze (EPM). Each F2 
mouse was transported individually in a clean transport cage from the vivarium to 
a separate testing room with red-illuminating ceiling lights that was designated for 
EPM testing. Each mouse was placed immediately into the center of the EPM 
(Stoelting Instruments, Wheaton, IL USA) and videotaped for 5 min using a 
webcam mounted to the ceiling. Our primary measure of the emotional-affective 
component of opioid withdrawal was percentage of time spent in the open arms 
[(open time)/(open time + closed time) *100)]. In contrast to rats (Schulteis et al., 
1998), opioid-dependent mice undergoing spontaneous withdrawal exhibit an 
increase rather than a decrease in time spent in the open arms of the EPM 
(Buckman et al., 2009; Hodgson et al., 2008; Hofford et al., 2009).  
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MA-induced locomotor activity  
 We tested parental strain mice (B6J n=31, B6NJ n=32) and a subset of 
NAL-treated F2 mice (N=184) for methamphetamine (MA)-induced locomotor 
activity. We utilized a five-day locomotor protocol, which is an extended version 
of our 3-day paradigm (Yazdani et al., 2015) that also allows for the assessment 
of locomotor sensitization. Immediately prior to placement in the locomotor 
chamber, we injected mice with SAL (10 ml/kg, i.p.) on D1 and D2. On D3, D4, 
and D5 mice received MA (2 mg/kg, 10 ml/kg, i.p.).  
Behavioral Analysis in B6J and B6NJ Mice 
 We tested the parental strains (B6J n=20, B6NJ n=12) for OXY-CPP with 
saline controls (B6J n=56, B6NJ n=46). In addition, we tested the parental strains 
for MA-induced locomotor activity (B6J n=31, B6NJ n=32) that had previously 
undergone NAL-CPA (mirroring the design for the F2 mice). All ANOVA analyses 
of behavioral measures were run in R (https://www.r-project.org/) with a 
significance threshold set for main effects and interactions to p=0.05. OXY-CPP 
and OXY-induced locomotor activity was analyzed first by three-way ANOVA 
(Sex, Strain, Treatment). Because we did not identify any Sex x Strain or Sex x 
Strain x Treatment interactions, we combined sexes and analyzed OXY-CPP by 
two-way ANOVA (Strain, Treatment), followed by Welch’s unequal variance t-
tests to determine the source of any Strain by Treatment interactions.  MA-
induced locomotor activity was first analyzed by a mixed design three-way 
ANOVA (Sex, Strain, Day as repeated measure).  Because we did not identify 
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any Sex x Strain or Sex x Strain x Day interactions, we combined sexes. 
Locomotor activity was analyzed by a mixed design two-way ANOVA (Strain, 
Day as repeated measure) followed by Welch’s unequal variance t-tests for the 
effect of Strain on each Day to determine the source of Strain by Day interaction.  
QTL analysis of F2 mice 
 To assess the effect of treatment on behaviors in F2 mice, drug-free 
CPP/CPA (D8-D1) and state-dependent CPP/CPA (D9-D1) and drug-induced 
locomotor activity (D2, D4) were analyzed (OXY-CPP vs SAL, NAL-CPA vs SAL) 
by Welch’s unequal variance t-tests.  
 All individuals were genotyped using a custom Fluidigm array consisting of 
96 SNP markers spaced approximately 30 Mb (approximately 15 cM) apart (Fig. 
3.1). This level of coverage is sufficient for mapping in an F2 cross because of the 
low number of recombination events. We recently used a nearly identical marker 
panel for QTL mapping in the RCC (Kirkpatrick et al., 2016). Markers were 
selected using high coverage sequence data for the C57BL/6NJ strain generated 
by the Welcome Trust Sanger Institute (Simon et al., 2013) and validated using 
traditional Sanger sequencing. Genomic DNA samples were diluted to 100 ng/uL 
in low TE buffer (Teknova, Hollister, CA, USA) and genotyped with approximately 
20% replication using the Fluidigm 96x96 SNPtype assay according to the 
manufacturer instructions (Fluidigm, South San Francisco, CA, USA). SNPs were 
called using the Fluidigm SNP Genotyping Analysis Software and SNPtype 
Normalization with the default 65% confidence threshold.  
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 Based on combined genotyping results from these samples (total F2 
n=634) and samples from our recently published study (Kirkpatrick et al., 2016) 
(F2 n=156), we eliminated 8 markers due to poor performance (greater than 25% 
missingness), and added 2 markers (via custom-design TaqmanSNP markers; 
Life Technologies, Carlsbad, CA) to genomic region containing QTLs with low 
marker coverage (Fig 3.1).  
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Figure 3.1: The genetic map used for QTL mapping.  
(A): F2 mice were genotyped using a 96 SNP array (Fluidigm, South San 
Francisco, CA, USA).  Based on combined genotyping results from these 
samples (total F2 n=634) and samples from our recently published study 
(Kirkpatrick et al., 2016) (F2 n=156), we eliminated 8 markers due to poor 
performance (greater than 25% missingness) and added 2 markers (via custom-
design TaqmanSNP markers; Life Technologies, Carlsbad, CA) to regions of the 
genome lacking adequate coverage to refine additional behavioral QTLs. This 
map represents the genetic map utilized for QTL mapping containing 90 
informative SNPs. The marker position (cM, centimorgan) was estimated using 
the sex-averaged position using the Mouse Map Converter 
(http://cgd.jax.org/mousemapconverter) (Cox et al., 2009).  
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 QTL analysis was performed in F2 mice using the R package R/qtl 
(Broman, Wu, Sen, & Churchill, 2003; Bryant, Chang, et al., 2009; Kirkpatrick et 
al., 2016).  Scanone function in R/qtl was used to calculate LOD scores. 
Permutation analysis (perm = 1,000) was used to establish the significance 
threshold for each phenotype (p < 0.05). Because our focus was on drug-induced 
behaviors, Treatment was included both as an additive and interactive covariate 
in the model to determine OXY- or NAL-specific QTLs. In addition, we also 
collapsed across Treatment to confirm that there was an effect of adding 
Treatment as a covariate.   
 The marker position (cM) was estimated using the sex-averaged position 
using the Mouse Map Converter (http://cgd.jax.org/mousemapconverter) (Cox et 
al., 2009). 95% Bayesian credible intervals were used to define the QTL 
intervals. The SNPs underlying the QTL interval were retrieved from the latest 
available datasets (http://www.sanger.ac.uk/). We used the equation                   
1 −10−2 LOD / n to estimate the proportion of trait variance accounted for by this 
QTL (n = sample size) (Nagelkerke, 1991). In addition, to make conclusions 
regarding Mendelian inheritance, we analyzed parental strain data to determine 
genetic variance.  
Comparative analysis of variants private to B6J but shared among B6NJ and 
classical inbred strains  
 We used the latest available dataset (REL-1505, 
http://www.sanger.ac.uk/) to retrieve variants (SNPs and indels) within protein-
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coding genes on chromosome 1 (172-178 Mb) to compare which variants are 
private to B6J but whose alternate allele is shared among B6NJ and classical 
inbred strains. Intriguingly, the QTL for oxycodone-induced locomotor activity 
mapped to the same precise location as a well-known QTL hotspot for addiction 
and motivational-affective traits (172-178 Mb) that was revealed from crosses 
that all contained the C57BL/6J strain versus four other classical inbred strains, 
including DBA/2J, BALB/cJ, C3H/HeJ, and LP/J (Mozhui et al., 2008). Genes 
containing a variant that is private to B6J and an alternate allele that is shared 
among B6NJ and all four classical inbred strains were further prioritized as 
candidate genes underlying behavior.  
Behavioral Analysis of Recombinant F2 mice 
 Based on the assumption that Day 2 OXY-induced locomotor activity was 
a Mendelian trait, we disregarded genotype across the genome, and focused on 
genotype at distal chromosome 1. 
F2 Recombinant Genotyping 
 We used the latest available dataset (REL-1505, 
http://www.sanger.ac.uk/) to retrieve SNPs underlying distal chromosome 1 (163-
190 Mb). Polymerase chain reaction (PCR) primers were designed for each SNP 
(at least 50 bp upstream and 20 bp downstream) using Primer3 
(http://bioinfo.ut.ee/primer3-0.4.0/primer3/). We used 50 ng/µl DNA in the PCR 
reaction and ran it through a 1% agarose gel via electrophoresis. We observed a 
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single band for each of the primer sets, excised it from the gel and extracted the 
PCR product using the QIAquick® gel extraction kit (Qiagen, Valencia, CA, 
USA). Samples weere sent to Genewiz (Genewiz, South Plainfield, NJ, USA) for 
Sanger sequencing.  Sequences were viewed using ABI Sequence Scanner 
(Applied Biosystems, Inc., Foster City, CA, USA).  Following successful 
sequencing, custom Taqman SNP assays were designed (Life Technologies, 
Carslbad, CA, USA).  Recombination events were then monitored using Taqman 
SNP assays with a mean distance of 4.25 cM between markers. Genomic 
coordinates are based on mm10 (Build 38), and marker position (cM) was 
estimated using the sex-averaged position using the Mouse Map Converter 
(http://cgd.jax.org/mousemapconverter) (Cox et al., 2009). 
Transcriptome Analysis 
 Striatum punches were collected for mRNA sequencing from 23 OXY-
treated F2 mice 24 hours after EPM testing. We chose mice that were either 
homozygous (J/J) or heterozygous (J/N) at the markers capturing a QTL on distal 
chromosome 1 for OXY-induced locomotor activity (rs6341208-163.13 Mb, 
rs51237371-181.32 Mb).  A sample size of 11-12 per genotype was employed (3-
4 females, 7-9 males per genotype). Brains were rapidly removed, sectioned with 
a brain matrix to obtain a 3 mm thick section, and a 2 mm diameter punch of the 
striatum was collected. Harvested left and right striatum punches were pooled 
and immediately placed in RNAlater (Life Technologies, Grand Island, NY, USA) 
for 48 h prior to storage in a -80 freezer. Total RNA was extracted as previously 
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described (Yazdani et al., 2016) using the RNeasy kit (Qiagen, Valencia, CA, 
USA). RNA was shipped to the University of Chicago Genomics Core Facility for 
cDNA library preparation using the Illumina TruSeq (oligo-dT; 100 bp paired-end 
reads). Libraries were prepared according to Illumina's detailed instructions 
accompanying the TruSeq® Stranded mRNA LT Kit (Part# RS-122-2101). The 
purified DNA was captured on an Illumina flow cell for cluster generation and 
sample libraries were sequenced at 23 samples per lane over 5 lanes (technical 
replicates) according to the manufacturer’s protocols on the Illumina HiSeq 4000 
machine, yielding an average of 69.4 million reads per sample. FASTQ files are 
quality checked via FASTQC and possessed Phred quality scores > 30 (i.e. less 
than 0.1% sequencing error). 
Differential Gene Expression Analysis 
 Using Rsubread (Liao, Smyth, & Shi, 2013), FASTQ files were used to 
align reads to the reference genome (mm10; UCSC Genome Browser) and read 
counts per gene were quantified.  A minimum of one read count per gene across 
all quadruplicates as well as a minimum of one count per million in at least 25% 
of the count files was required to be included in the analysis. Transcriptome 
analysis was implemented in the BioConductor package limma using the default 
TMM normalization and VOOM transformation (Ritchie et al., 2015). A linear 
model was employed where Genotype (across the Chr 1 QTL interval) was 
included as a factor, Cage was included as a covariate (Yazdani et al., 2016), 
and Sample Replicate was treated as a random effects measure to estimate 
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within-sample correlation using the lmFit() function to detect differential gene 
expression. We employed a cut-off of p<0.0001.   
Enrichment analysis 
 We applied pathway analysis (Ingenuity Pathway Analysis, IPA, 
www.qiagen.com/ingenuity) toward our differentially expressed gene list to 
identify enriched biological pathways, gene networks, and upstream regulators 
(Kramer et al., 2014) (see Kirkpatrick et al., 2016 for details).  IPA analyses were 
run in January 2017.  
Expression QTL Mapping 
 For expression QTL mapping, FASTQ files from each sample were 
summed across technical replicates, and Rsubread (Liao et al., 2013) was used 
to align reads to the reference genome (mm10; UCSC Genome Browser) and 
quantify read counts per gene. A minimum average of one FPKM per gene 
(across all samples) was required to be included in the analysis.  Linear 
regression was used to test the association between expression level of 12739 
genes and 90 SNPs with the R package Matrix eQTL (Shabalin, 2012). 
Genotypes were coded as 0, 1, or 2 to reflect an additive model. Sex and Cage 
were included as covariates. Due to the limited density of our SNP panel, we 
utilized a distance of 70 Mb (the largest distance between any two adjacent SNP 
markers in our genotyping panel) to define a cis-eQTL (p < 0.001). To determine 
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positional candidates for behavioral QTLs, we correlated expression of cis-eQTL 
genes within the QTL interval for each behavioral QTL.  
Results 
OXY-CPP in B6 substrains 
 We identified robust differences in OXY-induced locomotor activity 
between B6J and B6NJ in the CPP paradigm (Fig. 3.2a) with B6J exhibiting 
increased OXY-induced locomotor activity in comparison to B6NJ. Based on 
these values, the heritability of this trait is 25%. No differences in locomotor 
activity between SAL-treated B6J and B6NJ were identified (Fig. 3.2a). Similar to 
our previous findings with a OXY dose of 5 mg/kg in B6 substrains (Kirkpatrick & 
Bryant, 2015), we did not detect differences in OXY-CPP (D8-D1 time spent on 
the OXY-paired side) (Fig. 3.3a). 
QTL mapping of OXY behaviors 
 We focused our analyses on the identification of OXY-specific QTLs by 
combining OXY-CPP mice with SAL controls, and utilizing Treatment as both an 
additive and interactive covariate in our QTL model. OXY induced an increase in 
locomotor activity on D2 (Fig. 3.2b) and both drug-free OXY-CPP (D8-D1) and 
state-dependent OXY-CPP (D9-D1) in F2 mice (Fig 3.2c).  
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Figure 3.2: Variation in opioid phenotypes in B6 substrains warrants 
forward mapping.  
(A): Female and male B6J and B6NJ mice were tested for OXY (1.25 mg/kg, i.p.) 
and SAL (i.p.) place conditioning. A three-way ANOVA (Sex, Strain, Treatment) 
of Day 2 locomotor activity in the place conditioning paradigm did not identify Sex 
x Strain (F1,126=1.83, p >0.05) or Sex x Strain x Treatment (F1,126<1) interactions; 
therefore we collapsed across sexes (OXY N=12-20 per substrain and SAL 
N=46-56 per substrain). A two-way ANOVA (Strain, Treatment) identified a main 
effect of Strain (F1,130=9.22, p<0.01), a main effect of Treatment (F1,130=195.50, 
p<0.001), and a Strain by Treatment interaction (F1,130=11.41, p<0.001). To 
identify the source of this interaction, we completed post-hoc Welch’s t-tests 
corrected for four pairwise comparisons (p<0.05/4=0.0125). Post-hoc Welch’s t-
test indicated that B6J mice showed greater OXY-induced locomotor activity than 
B6NJ mice (t26=2.95, p<0.0125). Importantly, there was no difference in SAL 
activity between B6J and B6NJ (t94<1). Both substrains exhibited increased 
locomotor activity in response to OXY (B6J: t23=9.76, p<0.0125; B6NJ: t13=5.13, 
p<0.0125). (B):  Locomotor activity on drug training days (D2, D4) for all place 
conditioning F2 mice (NAL N=209, SAL N=213, OXY N=212). Welch’s t-test for 
unequal variance was used to identify an effect of Treatment on locomotor 
activity compared to SAL-treated mice. NAL-treated F2s (4 mg/kg, i.p.) exhibited 
slightly decreased locomotor activity on D2 (t409=2.89, p<0.01) and D4 (t415=4.31, 
p<0.01). OXY-treated F2s (1.25 mg/kg, i.p.) exhibited increased locomotor activity 
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on D2 (t267=14.77, p<0.0001) and D4 (t239=15.27, p<0.0001). (C): Change in time 
spent on the drug-paired side between drug-free assessment and initial 
preference (D8-D1), and state-dependent assessment and initial preference (D9-
D1) for all F2 mice undergoing place conditioning. Welch’s t-test for unequal 
variance was used to identify an effect of treatment on time spent on the drug-
paired side compared to SAL-treated mice. NAL-treated F2s (4 mg/kg, i.p.) 
exhibited significant drug-free (D8-D1 t417=5.57, p<0.0001) and state-dependent 
(D9-D1 t417=7.32, p<0.0001) CPA. OXY-treated F2s (1.25 mg/kg, i.p.) exhibited 
significant drug-free (D8-D1 t421=6.46, p<0.0001) and state-dependent (D9-D1 
t402=7.54, p<0.0001) CPP. Data are represented as the mean ± SEM; 
NAL=naloxone; OXY=oxycodone; SAL= saline; m.=meters; s.=seconds; D=day; 
CPA= conditioned place aversion; CPP= conditioned place preference.  
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Figure 3.3: B6J and B6NJ do not differ in OXY-CPP. 
(A): Male and female B6J and B6NJ mice were tested for OXY (1.25 mg/kg, i.p.) 
and SAL (i.p.) place conditioning. A three-way ANOVA (Sex, Strain, Treatment) 
of preference (D8-D1 time on the OXY-paired side) did not identify Sex x Strain 
(F1,126<1) or Sex x Strain x Treatment (F1,126=1.82, p>0.05) interactions; therefore 
we collapsed across sexes (OXY N=12-20 per substrain and SAL N=46-56 per 
substrain). A two-way ANOVA (Strain, Treatment) identified an effect of 
Treatment (F1,130=8.58, p<0.05) but no Strain x Treatment interaction (F1,130 <1). 
Data are represented as the mean ± SEM; OXY=oxycodone; SAL= saline; D8= 
Day 8; D1= Day 1; s.=seconds. 
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 We identified a single genome-wide significant QTL on distal chromosome 
1 that mediated OXY-induced locomotor activity on the first exposure to the drug 
(Fig. 3.4a,b). Although there is a peak on chromosome 19 above the LOD 
threshold, it did not reach significance (p=0.11). The QTL signal at the peak 
marker on chromosome 1 was driven by allelic differences in the same 
phenotypic direction as the parental strains (B6J > B6NJ) with no effect of 
genotype on locomotor activity in SAL controls (Fig. 3.4c).  The effect plot (Fig. 
3.4c) supports a dominant model of inheritance, with 1 copy of the NJ allele 
decreasing OXY-induced locomotor activity to similar levels of mice with 2 copies 
of the NJ allele. This QTL accounts for 19.16% of the total variance in OXY-
induced locomotor activity.  
 The locus on distal chromosome 1 was also identified for numerous 
behaviors related to the locomotor stimulant properties of OXY on both first (D2) 
and second (D4) exposure to OXY, including spins and rotations (Kirkpatrick & 
Bryant, 2015) (Fig. 3.4d), further confirming a reliable role of this locus in 
mediating OXY sensitivity. Importantly, the effect of Genotype at the closest 
marker for these additional phenotypes mirrored those of D2 distance (Fig. 3.5).  
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Figure 3.4: A locus on distal chromosome 1 regulates OXY sensitivity and 
withdrawal.  
(A): A single genome-wide significant QTL for OXY- induced locomotor activity 
on D2, was identified on chromosome 1 (LOD= 9.79, p=0.001, 83.33 cM). The 
horizontal line represents the LOD threshold.  The 95% Bayes confidence 
interval spans approximately 11 Mb (Chr 1 170995866-181318258, mm10). 
Although a peak on chromosome 19 surpassed the LOD threshold, it did not 
pass genome-wide significance testing (p=0.11). (B): This same locus on distal 
chromosome 1 regulates numerous other measures of OXY sensitivity (all 
peaking at 83.33 cM), including D2 spins (LOD=12.67, p<0.001), D2 rotations 
(LOD=13.22, p<0.001), D4 distance (LOD=8.88, p<0.01), D4 Spins (LOD=10.07, 
p<0.01), and D4 rotations (LOD=12.57, p<0.001).  (C): The effect plot for D2 
distance is for the closest marker to the QTL peak (rs51237371, 84.58 cM). Mice 
that are J/J at this marker exhibit increased OXY-induced locomotor activity 
compared to those that are J/N or N/N. Data are represented as the mean ± 
SEM. (D,E): We identified a single genome-wide significant QTL for OXY 
withdrawal behavior in the elevated plus maze that overlapped largely with the 
QTL for acute OXY sensitivity on distal chromosome 1 (LOD=4.73, p<0.05, 76.33 
cM). The 95% Bayes confidence interval spans approximately 29 Mb (Chr 1 
151744187-180490015, mm10). (F): The effect plot is shown for the marker 
closest to the QTL peak (rs6341208, 72.42 cM). Mice that were J/J at this marker 
exhibited an increase in OXY-induced percent open arm time compared to those 
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that are J/N or N/N. Data are represented as the mean ± SEM. OXY=oxycodone; 
SAL= saline; m.=meters; s.=seconds; D=day; cM= centimorgan, Mb= megabase. 
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Figure 3.5: Effect plots for other behaviors indicative of OXY sensitivity that 
possess a QTL at distal chromosome 1.  
(A-F): A locus on distal chromosome 1 mediates numerous sensitivity 
phenotypes for both the first (D2: A, B, C) and second (D4: D, E, F) exposure to 
OXY. Effect plots are shown for the closest marker to the QTL peak 
(rs51237371, 84.58 cM, 181.3 Mb). Mice that are J/J at this marker exhibit 
increased OXY-induced activity (Distance, Spins, Rotations) compared to those 
that are J/N or N/N. Data are represented as the mean ± SEM; OXY=oxycodone; 
SAL= saline; m.=meters; s.=seconds; D=day; cM= centimorgan, Mb= megabase.  
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QTL mapping of OXY withdrawal 
 A subset of the F2 mice tested for OXY-CPP or SAL controls received 
chronic treatment (4 days once daily, 3 days off, 4 days once daily) with either 
high dose OXY (20 mg/kg) or SAL, respectively and were then tested on the 
elevated plus maze (EPM) within 24 hours of their last injection. We identified an 
OXY-specific genome-wide significant QTL for percent open arm time (Fig. 
3.4d,e), with mice homozygous B6J at the closest marker exhibiting increased 
open arm time relative to mice homozygous B6NJ at the closest marker (Fig. 
3.4f). In contrast to rats (Schulteis et al., 1998), opioid-dependent mice exhibit an 
increase rather than a decrease in time spent in the open arms of the EPM 
(Buckman et al., 2009; Hodgson et al., 2008; Hofford et al., 2009). The 95% 
Bayes confidence interval spans approximately 29 Mb (Chr 1 151744187-
180490015, mm10). Importantly, this represents an overlap of approximately 9.5 
Mb with the QTL confidence interval for Day 2 OXY-induced locomotor activity.  
Comparative analysis of variants private to B6J but shared among B6NJ and 
classical inbred strains associated with a distal chromosome 1 hotspot for 
multiple neurobehavioral phenotypes. 
 Intriguingly, the QTL on distal chromosome 1 for OXY-induced locomotor 
activity mapped to the same precise location as a well-known QTL hotspot for 
addiction and motivational-affective traits (172-178 Mb) that was revealed from 
crosses that all contained the C57BL/6J strain versus four other classical inbred 
strains, including DBA/2J, BALB/cJ, C3H/HeJ, and LP/J (Mozhui et al., 2008). 
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These observations led to a specific hypothesis, namely that one or more private 
variants within B6J relative to the alternate allele shared among B6NJ and these 
other strains underlies the QTL hotspot. To reveal private B6J variants, we 
compiled a list all variants (SNPs and indels) within protein-coding genes 
between 172-178 Mb between B6J and B6NJ. Genes containing a variant that is 
private to B6J and an alternate allele that is shared among B6NJ and all four 
classical inbred strains were further prioritized as candidate genes underlying 
behavior. In considering the 41 variants within genes, only 12 were identified in 
the queried inbred strains (Table 3.1). This comparative analysis identified seven 
genes meeting this criterion, including Ccdc19, Cadm3, Aim2, Fmn2, Grem2, 
Rgs7, and 1700016C15Rik .  
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Table 3.1: Comparative analysis of variants private to B6J but shared 
between B6NJ and classical inbred strains associated with a distal 
chromosome 1 hotspot for multiple neurobehavioral phenotypes. 
 
The position of the SNP (Mb), the gene ID, the SNP information (denoted by 
reference SNP cluster ID if it has one), the allele in the reference strain 
(C57BL/6J), and the variant allele in C57BL/6NJ and 3 inbred strains (DBA/2J, 
BALB/cJ, C3H/HeJ, LP/J) are listed. All positions based on GRCm38 mouse 
reference build mm10.  
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Replication of the OXY QTL in F2 recombinants  
 We tested F2 recombinants in an abbreviated CPP paradigm (Day 1 SAL, 
Day 2 1.25 mg/kg OXY) (Fig. 3.6a,b). We chose 3 F2 mice to backcross to B6J 
based on their genotypes at distal chromosome 1 (Fig. 3.6c). Recombination 
events were monitored using SNP assays across distal chromosome 1, and 
offspring with desired recombinations were paired as additional breeders. 
Currently, we are underpowered to detect effects of individual families, and as 
such, collapsed across all mice. There was no effect of genotype across distal 
chromosome 1 on baseline locomotor activity (Fig 3.6a). The effect of Genotype 
at distal chromosome 1 in the F2 recombinants (Fig. 3.6b) mirrors that seen in 
the QTL analyses, with B6J mice exhibiting increased OXY-induced locomotor 
activity, relative to mice that are homozygous across distal chromosome 1.  
QTL mapping of baseline nociception 
 We did not identify any QTLs for OXY-induced analgesia in this F2 cross 
(data not shown). However, we identified a single genome-wide locus on 
chromosome 7 for baseline nociception (Fig. 3.7a,b). Previous treatment (OXY 
or SAL) did not interact with the effect of the locus of baseline nociception (LOD 
without covariate = 3.81, p<0.01; LOD with covariate = 3.72, p<0.01); therefore 
we collapsed across previous treatment (n=164). A difference in baseline 
nociception between B6 substrains was identified and replicated previously 
(Bryant et al., 2008; Matsuo et al., 2010) but this represents the first effort to 
identify the genetic variation mediating the phenotypic difference. Importantly, the 
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QTL signal was driven by allelic differences in the same phenotypic direction as 
previously published data (B6NJ > B6J, Fig. 3.7c) with an additive mode of 
inheritance.  
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Figure 3.6: Fine mapping of OXY sensitivity in RCC F2 recombinants.  
(A, B) We tested F2 recombinants in an abbreviated CPP paradigm (Day 1 SAL, 
Day 2 1.25 mg/kg OXY). (C) We chose 3 F2 mice to backcross to B6J based on 
their genotypes at distal chromosome 1. Recombination events were monitored 
using SNP assays across distal chromosome 1 (designated as red lines across 
the diagram).  Black regions represent homozygous B6J, grey regions represent 
heterozygous (B6J/B6NJ) and white regions denote unknown break points. 
Offspring with desired recombination events were paired as additional breeders. 
Currently, we are underpowered to detect effects of individual families, and as 
such, collapsed across all mice. 
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Figure 3.7: QTL for baseline thermal nociception on chromosome 7  
(A, B): A single genome-wide significant QTL for baseline latency to lick the 
hindpaw in the 52.5 degree hot plate assay was identified on chromosome 7 
(LOD=3.72, p<0.05, 17.4 cM). There was no effect of including previous 
Treatment (OXY, SAL) as a covariate in the QTL model (LOD without covariate = 
3.81, p<0.01; LOD with covariate = 3.72, p<0.01); thus we collapsed across 
previous Treatment (N=164). The 95% Bayes confidence interval spans 
approximately 27 Mb (Chr 7 8736811-36504095, mm10). (C): The effect plot for 
the closest marker to the QTL peak (rs3148686, 17.41 cM) suggests an additive 
effect. Mice that are J/J at this marker showed decreased latency to lick the 
hindpaw, with mice that are J/N at this marker showing intermediate latency, and 
mice that are N/N at this marker showing the highest latency. Data are 
represented as the mean ± SEM. OXY=oxycodone; SAL= saline; s.=seconds; 
cM= centimorgan, Mb= megabase. 
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QTL mapping of NAL behaviors 
 We focused our analyses on the identification of NAL-specific QTLs by 
combining NAL-CPA mice with SAL controls, and utilizing treatment as both an 
additive and interactive covariate in our QTL model. NAL treatment produced 
drug-free NAL-CPA (D8-D1) state-dependent NAL-CPA (D9-D1) in F2 mice (Fig 
3.2c). We were unable to identify any genome-wide QTLs for NAL-CPA or state-
dependent NAL-CPA in the RCC. However, we identified a genome-wide 
significant QTL on chromosome 18 for state-dependent freezing on the NAL-
paired side (D9 right freezing bouts) that overlapped with the difference in state-
dependent freezing and freezing on the first assessment day (D9-D1 right 
freezing bouts; Fig. 3.8a,b). This signifies that this locus mediates state-
dependent freezing that is not dependent on baseline freezing bouts.  
 Using exploratory factor analysis, we previously identified a relationship 
between NAL-induced freezing behaviors and NAL-CPA, and thus identified this 
behavior as a motivational component of the overall aversive response to NAL 
(Kirkpatrick & Bryant, 2015). The effect plot at the peak marker mirrors the 
parental strain differences in NAL-CPA; with NAL-treated homozygous J mice 
exhibited increased NAL-induced freezing compared to homozygous NJ mice 
(Fig. 3.8c).  
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Figure 3.8: QTL for state-dependent NAL-induced freezing on chromosome 
18  
 (A, B): A single genome-wide significant QTL for state-dependent NAL-induced 
freezing was identified on chromosome 18. The QTL was identified for D9-D1 
freezing on the right side (NAL-paired side) (LOD=6.24, p<0.01, 24.87 cM). (C): 
The effect plot for the marker closest to the QTL peak (rs13483369 54.61 Mb) 
shows that J/J mice exhibit an increase in NAL-induced freezing following 
training compared to mice that are J/N or N/N at the peak marker. Data are 
represented as the mean ± SEM. NAL=naloxone; SAL= saline; D= day; cM= 
centimorgan, Mb= megabase. 
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 Because of the effect of Genotype at the peak marker on SAL D9-D1 
freezing, we were concerned that the effect of the QTL may be driven by an 
interaction of the QTL and SAL freezing. Therefore, we mapped each treatment 
separately (data not shown), and identified a significant QTL at the same locus in 
the NAL-treatment group (LOD=4.25, p<0.05, 22.9 cM), but not the SAL-
treatment group (LOD=2.54, p=0.3, 27.9 cM).  
 A locus slightly proximal to this was identified for the change in mean visit 
time on the NAL-paired side between D8 and D1, and between D9 and D1. The 
95% Bayes confidence interval spans 60.3 Mb (12970828-73282930, mm10) for 
D8-D1 mean visit time on the NAL-paired side and spans 49.3 Mb for D9-D1 
mean visit time on the NAL-paired side (14072401-63346339, mm10) (Fig. 3.9a).  
In addition, we identified a region on chromosome 5 that affected NAL-CPA 
related behaviors, including distance traveled on the side of retreat on state-
dependent test day (D9 Left Distance) and time freezing on state-dependent test 
day (D9) (Fig. 3.9b). The QTL for these behaviors peak near each other, with the 
95% Bayes confidence interval spanning approximately 52.5 Mb for D9 Left 
distance (Ch5 42775666-95351027, mm10) and 33.1 Mb for D9 Time Freezing 
(Ch5 66271585-99388775, mm10).  
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Figure 3.9: Additional QTLs for NAL aversion-associated phenotypes 
identified on chromosomes 5 and 18. 
(A): Overlapping QTLs were identified for the change in mean visit time on the 
NAL-paired side between D8 and D1 (LOD=4.08, p<0.01, 17.87 cM), and 
between D9 and D1 (LOD= 3.65, p=0.07, 17.87 cM). The 95% Bayes confidence 
interval spans 60.3 Mb (12970828-73282930, mm10) for D8-D1 mean visit time 
on the NAL-paired side and spans 49.3 Mb for D9-D1 mean visit time on the 
NAL-paired side (14072401-63346339, mm10). (B): A region on chromosome 5 
affects distance traveled on the side of retreat on state-dependent test day (D9 
Left Distance; LOD=4.56, p<0.05, 37.56 cM) and time freezing on state-
dependent test day (D9 Time Freezing; LOD=5.17, p=0.05, 37.37 cM). The QTL 
for these behaviors peak near each other, with the 95% bayes confidence 
interval spanning approximately 52.5 Mb for D9 Left distance (Ch5 42775666-
95351027, mm10) and 33.1 Mb for D9 Time Freezing (Ch5 66271585-99388775, 
mm10). NAL=naloxone; SAL= saline; s.=seconds; cM= centimorgan, Mb= 
megabase. 
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MA-induced locomotor activity in B6 substrains  
 We aimed to replicate a previous study (Kumar et al., 2013) identifying a 
B6 substrain difference in MA-induced activity at the 2 mg/kg dose in our 5-day 
locomotor activity paradigm. We identified a significant difference between B6J 
and B6NJ in D1 locomotor activity (SAL treatment), with B6NJ showing 
decreased locomotor activity relative to B6J (Fig. 3.10a), which may be 
representative of an anxiety-prone phenotype in B6NJ mice. Previous studies 
have identified decreased activity in open field behavior in B6NJ compared to 
B6J (Ashworth et al., 2015; Matsuo et al., 2010). There was no difference on D2 
in response to SAL (Fig. 3.10a). We identified significantly increased MA-induced 
locomotor activity in B6J compared to B6NJ mice on all MA treatment days (D3-
D5; Fig. 3.10a). 
QTL for MA-induced locomotor activity on chromosome 5  
 We identified a genome-wide significant QTL for Day 3 MA-induced 
locomotor activity on chromosome 5 (Fig. 3.10b,d).  An effect plot showed that 
mice homozygous for the B6J allele at the peak marker exhibited increased MA-
induced locomotor activity relative to mice homozygous for the B6NJ allele at the 
peak marker (Fig. 3.10c), mirroring the phenotyping differences exhibited in the 
parental strains (B6J > B6NJ, Fig. 3.10a).  
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Figure 3.10: QTL for MA-induced locomotor activity on chromosome 5  
(A) Female and male B6J and B6NJ mice were tested for MA-induced locomotor 
activity. On D1 and D2, mice were treated with SAL, and on D3-D5, mice were 
treated with MA (2 mg/kg). A three-way mixed design ANOVA (Sex, Strain, Day 
as repeated measure) of locomotor activity did not identify a Sex x Strain (F1,305 
<1) or Sex x Strain x Day (F1,305 <1) interactions; therefore we collapsed across 
sexes (B6J N=31, B6NJ=32). A two-way mixed Design ANOVA (Strain, Day as 
repeated measure) identified a Strain by Day interaction (F1,309=39.45, p<0.001). 
To identify the source of this interaction, we completed post-hoc Welch’s t-test for 
effect of Strain on each day corrected for five group-wide comparisons 
(p<0.05/5=0.01). B6J exhibited increased locomotor activity on D1 (t60=3.10, 
p<0.01), but this difference was not significant on D2 (t59<1). MA treatment 
resulted in greater locomotor activity in B6J compared to B6NJ on all three MA 
treatment days (D3 t56=7.37, p<0.01;D4 t60=9.41, p<0.01; D5 t60=9.16, p<0.01). 
(B, D) A single genome-wide significant QTL for MA-induced locomotor activity 
on D3 was identified on chromosome 5 (LOD= 3.86, p<0.05, 35.37 cM). (C): The 
effect plot for the closest marker to the QTL peak (rs29547790 70.93 Mb) shows 
that J/J mice exhibit increased MA-induced locomotor activity on D3 compared to 
mice that are J/N or N/N at the peak marker. This mirrors the phenotypic 
differences exhibited by the parental strains, with the locus exhibiting an additive 
mode of inheritance.. The 95% Bayes confidence interval spans approximately 
47 Mb (Ch 5 52004899-99388775, mm10). Data are represented as the mean ± 
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SEM. MA=methamphetamine; SAL= saline; m.=meters; cM= centimorgan, Mb= 
megabase. 
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 Previously, a missense mutation in Cyfip2 in the B6N allele was shown to 
underlie decreased cocaine-induced locomotor activity (Kumar et al., 2013). 
Based on the similarity in B6 substrain difference with cocaine and MA, we 
expected to identify an association between the Cyfip2 locus and MA-induced 
locomotor activity; however we did not identify this QTL in our genome-wide scan 
or observe an effect of Genotype at this locus on D3 distance (data not shown).  
Transcriptome of OXY-treated F2 mice 
 To gain insight into neurobiological mechanisms that link genetic variation 
in the identified locus on distal chromosome 1 with differences in OXY sensitivity 
and withdrawal (Fig 3.11a), we conducted RNA-seq and transcriptome analysis 
in a subset of OXY-treated F2 mice. The selected mice exhibited OXY-induced 
locomotor activity analogous to the larger dataset (Fig. 3.2a), with mice 
homozygous J across the interval exhibiting increased OXY-induced activity (Fig. 
3.11b) and increased OXY-induced withdrawal behavior in the EPM (Fig. 3.11c), 
compared to mice that are heterozygous across the interval. We identified 629 
differentially expressed genes in mice heterozygous for the OXY sensitivity QTL 
compared to those that are homozygous J across the interval (411 
downregulated genes, 218 upregulated genes).  
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Figure 3.11: Striatal transcriptomic analysis in OXY-withdrawn F2 mice 
identifies key network with MAPT and APP as hub genes.  
(A) There is a10 Mb overlapping between the OXY D2 distance QTL interval and 
the OXY withdrawal interval. We selected OXY-withdrawn mice for RNAseq 
based on genotypes at the markers flanking this 10 Mb region (flanking markers: 
J/J vs. J/N). (B) Effect plots are shown for J/J (n=11) vs J/N mice (n=12). (A): 
The effect of Genotype on OXY D2 locomotor activity mirrors that of the larger 
dataset, with mice homozygous J across the interval exhibiting increased OXY-
induced activity compared to mice that are heterozygous across the interval 
(t21=2.99, p<0.01). (C): The effect of Genotype on percent open arm time, a 
measurement of OXY withdrawal behaviors, is more variable in the smaller 
subset of mice. Although the effect of genotype on the behavior is not significant 
(t17=0.86, p=0.4), it mirrors the same trend as seen in the larger dataset, with 
mice that are homozygous J across the interval exhibiting increased open arm 
time compared to mice that are heterozygous across the interval. Data are 
represented as the mean ± SEM; OXY=oxycodone; m.=meters; Mb=megabase; 
cM=centimorgan. (D) The top IPA network identified was “Cell-To-Cell Signaling 
and Interaction, Nervous System Development and Function, Molecular 
Transport”. All 70 genes within the network are differentially expressed in our 
gene list (Score=85). This network includes 54 down-regulated genes (green) 
and 16 up-regulated genes (red), and two major hub genes (APP, MAPT).  
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 To narrow the list of potential candidate genes underlying the QTL, we 
identified 9 genes that were differentially expressed in the larger QTL interval for 
OXY withdrawal and only 5 of these overlapped with the QTL interval for acute 
OXY sensitivity (Table 3.2). Overall, only 4 of these genes were associated with 
genetic variation that could potentially regulate expression (Table 3.2). When 
considering only the overlapping interval between the QTL for OXY sensitivity 
and OXY withdrawal, only 2 genes (Cadm3, Aim2) are associated with genetic 
variation that could regulate their expression.  
 We also aimed to utilize pathway analysis to identify downstream 
neurobiological mechanisms that could regulate opioid-induced behaviors as a 
function of chromosome 1 genotype. Ingenuity pathway analysis identified Cell-
To-Cell Signaling and Interaction, Nervous System Development and Function, 
Molecular Transport (score=85, Fig. 3.10d). This network contains two major hub 
genes, MAPT and APP. The top effector network was identified as MAPT, with a 
predicted effect of cell death of cortical neurons. MAPT was also identified as 
one of the top upstream regulators (Activated, p-value=9.84E-11), in addition to 
ADORA2A (inhibited, p-value=6.24E-12), and MKNK1 (Inhibited, p-value=3.63E-
10). The top diseases annotation category was Neurological Disease (p-
value=3.81E-02 - 1.47E-13) with 200 molecules. The top physiological system 
development and function annotation was Nervous System Development and 
Function (p-value =3.81E-02 - 1.76E-12) with 190 molecules.  
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Table 3.2: Differentially expressed genes within the chromosome 1 QTL 
interval for OXY-induced locomotor activity and withdrawal.  
Differentially expressed genes within the QTL interval for OXY withdrawal and 
sensitivity are listed. Associated phenotype, Chromosome (Chr.), Gene start 
position (mm10), gene ID, gene description, adjusted P-value, FC, and number 
of SNPs within that gene between B6J and B6NJ are listed. All positions are 
based on GRCm38 mouse reference build mm10. Genes that contain SNPs 
between B6J and B6NJ are denoted in bold. Mb= Megabase, FC=fold-change, 
FDR=false discovery rate. 
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Expression QTL mapping  
 A total of 491 cis-eQTLs were identified in the striatum of a subset of 
OXY-treated F2 mice (p<0.01). We focused on cis-eQTL genes within the QTL 
interval of each of our behavioral QTLs to further prioritize positional candidates 
(Table 3.3). A positional candidate was defined as a gene within the 95% Bayes 
Interval of a behavioral QTL that exhibited a significant cis-eQTL in the striatum. 
We identified 8 positional candidates for percent open arm time (Qsox1, Cep350, 
Mrps14, Alyref2, Ncstn, Aim2, Rgs7, Desi2), and 5 of these also overlapped with 
the interval for OXY D2 Distance. A 6th positional candidate (Sde2) was also 
identified for OXY D2 Distance.  
 We identified seven positional candidates for MA D3 Distance (Klf3, 
Slc30a9, Gabra2, Commd8, Pdgfra, Cox18, Mrpl1) (Table 3.3). Gabra2 encodes 
the alpha 2 subunit of the gamma-aminobutryic acid A (GABA-A) receptor, and is 
a noteworthy positional candidate. Gene variants in GABRA2 have been 
associated with risk for cocaine addiction in humans (Dixon et al., 2010; Enoch et 
al., 2010). In addition, SNPs in GABRA2 can affect sensitivity to another 
psychostimulant, methylphenidate (Duka et al., 2015). Therefore, it is plausible 
that genetic variation in Gabra2 could be affecting sensitivity to multiple 
psychostimulants, including methamphetamine.  
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Table 3.3: Positional candidate genes for multiple addiction-associated 
behaviors.  
A positional candidate gene was defined as a gene within the 95% Bayes Interval 
of a behavioral QTL that exhibited a significant striatal cis-eQTL (p<0.01). 
Included in the table is the phenotype, the associated SNP (denoted by reference 
SNP cluster ID) and position (Mb), the start position of the gene (Mb), the gene 
ID, full gene name, and p-value (as calculated by Matrix eQTL). All positions are 
based on GRCm38 mouse reference build mm10. 
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 We only identified one positional candidate for NAL state-dependent 
freezing bouts (Pcdhb18). Furthermore, Onecut2, was located just 2 Mb outside 
of the interval for NAL state-dependent freezing bouts (Chr 18 64 Mb). Onecut2 
is a member of a family of genes encoding transcription factors that are essential 
for development of multiple neuronal populations, including motor neurons and 
dopaminergic neurons (Chakrabarty et al., 2012; Kropp & Gannon, 2016). In 
addition, Onecut2 plays an integral role in the development of the locus 
coeruleus (Espana & Clotman, 2012), a key brain region for opioid withdrawal 
(Van Bockstaele, Reyes, & Valentino, 2010).  
 Because the mice utilized for RNA-seq had undergone OXY-CPP and 
OXY-EPM, we could utilize gene expression correlation to further prioritize 
positional candidates, defined as a gene within the 95% Bayes Interval of a 
behavioral QTL that exhibited a significant cis-eQTL in the striatum and 
significantly covaried in expression with the behavioral trait (Fig 3.12). Pearson’s 
correlation of cis-eQTL gene expression with OXY sensitivity (D2 distance) 
and/or withdrawal (% open arm time) was performed. Using this definition, three 
high priority positional candidates were identified for D2 Distance (Aim2, Rgs7, 
and Sde2), and two high priority positional candidates were identified for percent 
open arm time (Mrps14, Rgs7). The only gene that significantly co-varied with the 
expression of both phenotypes was Rgs7. Due to the 9.5 Mb overlap of the QTL 
confidence intervals for OXY sensitivity and OXY withdrawal, it is possible that 
one gene (Rgs7) mediates both phenotypes. Rgs7 expression was positively 
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correlated with both OXY sensitivity and withdrawal (Fig. 3.12b,c). Importantly, 
Rgs7 was identified through our comparative analysis of variants private to B6J 
but shared between B6NJ and classical inbred strains associated with a distal 
chromosome 1 hotspot for multiple neurobehavioral phenotypes. Furthermore, 
RGS7, regulator of G-protein signaling 7, has previously been identified as a 
regulator of mu-opioid receptor signaling, regulating opioid reward and 
withdrawal (Sutton et al., 2016). Thus, we conclude that Rgs7 is the most likely 
candidate gene on distal chromosome 1 underlying opioid behaviors.   
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Figure 3.12: Rgs7 is a high priority positional candidate for OXY sensitivity 
and withdrawal. 
 (A): Pearson’s correlation of cis-eQTL gene expression (FPKM) with OXY 
sensitivity (D2 distance) and/or withdrawal (percent open arm time) was 
performed. Correlations were only tested if the gene was within the 95% Bayes 
interval of a behavioral QTL (t-test for non-zero Pearson’s r, degrees of 
freedom=21). Pearson’s r is included for all correlations, and t-value and p-value 
are included if the correlation is suggestive (p<0.1) or significant (p<0.05). (B, C): 
D2 distance and percent open arm time in the elevated plus maze after chronic 
OXY treatment, as a measure of OXY withdrawal, both positively correlate with 
striatal Rgs7 expression (r2=0.28; r2=0.15). Genotype cross the QTL interval is 
identified as either a black (J/J) or grey (J/N) marker in the correlation plots.  All 
positions based on GRCm38 mouse reference build mm10. Mb=megabase; D= 
day; m.=meters. 
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Discussion 
 We used a systems genetic approach in a cross comprising reduced 
genetic complexity to rapidly and efficiently identify high priority candidate genes 
underlying behavioral addiction traits associated with opioids and 
psychostimulants. An important feature of our experimental design was the 
inclusion of a SAL control group in our mapping studies, which permitted the 
inclusion of Treatment as a covariate in the QTL model to control for genetic 
variation responsible for phenotypic variation that was not specific to drug 
treatment.  
 By analyzing multiple drugs (OXY, MA, NAL) and multiple behavioral 
phenotypes (CPP/CPA, locomotor activity, spins, rotations, freezing, etc.), we 
were able to identify loci that were drug- or phenotype specific, as well as, loci 
that mediated multiple behavioral responses. Notably, we identified separate loci 
for opioid-induced (Fig. 3.4) and psychostimulant-induced locomotor activity (Fig. 
3.10). Furthermore, the opioid locus on chromosome 1 exerted pleiotropic effects 
on multiple OXY-induced behaviors, including responses on the first (D2) and 
second (D4) exposure to the drug as well as opioid-induced rotational behaviors 
that can be induced by microinjection of a mu opioid receptor agonist into the 
striatum (Iwamoto & Way, 1977; Matsumoto, Brinsfield, Patrick, & Walker, 1988). 
Pleiotropy of correlated behaviors provides further confidence that the chr. 1 
locus contains variant(s) critical for opioid behavioral addiction traits. Finally, we 
identified distinct QTLs for freezing behaviors and change in visit time that were 
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specific to prior NAL administration and that we previously showed to be 
correlated with NAL-CPA (Kirkpatrick and Bryant, 2015). These observations 
further illustrate how forward genetic analysis of phenotypically rich datasets of 
multiple drug-induced behaviors can inform biology and identify genetic loci 
contributing to heritable traits. 
 In contrast to a 5 mg/kg dose of OXY where we did not observe any B6 
substrain difference in OXY-induced locomotor activity (Kirkpatrick and Bryant, 
2015), here, we identified a significant difference at 1.25 mg/kg dose of OXY 
(B6J > B6NJ) and we mapped a major QTL on distal chromosome 1 accounting 
for this difference. As expected, based on the lack of parental strain difference in 
OXY-CPP at 1.25 mg//kg OXY, we did not identify any significant QTL for OXY-
CPP. Genetic effects on drug-induced locomotor sensitivity can sometimes, 
although not always predict genetic differences in drug reward and 
reinforcement. Here, we identified a QTL for opioid locomotor activity but not 
reward. In a previous study of OXY-CPP in an advanced intercross line, we did 
not identify a correlation of D2 OXY-induced locomotor activity and OXY-CPP 
and additionally found that OXY-CPP displayed limited heritability (Bryant et al., 
2014). Thus, although these two phenotypes are biologically connected, they 
may be genetically independent.   
 Although we previously identified robust substrain differences in both 
drug-free and state-dependent NAL-CPA (Kirkpatrick & Bryant, 2015), we did not 
detect QTL for either of these phenotypes. These null results could potentially be 
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explained by several issues, including the inherent environmental noise in place 
conditioning studies that likely limits heritability (Bryant et al., 2014) and thus, 
limits the power to detect QTLs. Knowing the utility of place conditioning with 
regard to face validity of motivational behavior yet the limitations of this behavior 
as a stand-alone trait for genetic mapping studies, we previously sought to 
identify additional behaviors that correlated with preference or aversion where we 
used exploratory factor analysis to identify an increase in conditioned freezing 
bouts in response to NAL that loaded onto a common aversion factor (Kirkpatrick 
& Bryant, 2015), providing evidence that freezing behavior is a component of 
NAL-aversion  Accordingly, we applied these phenotypes toward QTL analysis  
and identified multiple loci for aversion-relevant behaviors on chromosome 5 
(Fig. 3.9b) as well as a major locus on chromosome 18 influencing state-
dependent freezing on chromosome 18 (Fig.3.8, Fig. 3.9a). Exploratory factor 
analysis led to the identification of freezing behavior as a component of NAL-
aversion. Thus, although we did not identify a QTL for NAL-CPA, the QTLs for 
freezing behaviors contain genetic variants relevant to to the negative-affective 
motivational state induced by NAL treatment.   
 The QTL interval for OXY sensitivity largely overlaps with a QTL for OXY 
withdrawal and thus, if we assume that there is a common underlying genetic 
factor, we have reduced the interval to 171.0-180.5 Mb, suggesting a common 
underlying genetic factor and a specific hypothesis, namely, that increased acute 
behavioral sensitivity to OXY (B6J allele) leads to increased opioid withdrawal. 
  
161
The 95% Bayes interval for these OXY behavioral QTLs is still quite large (D2 
Distance: Chr1 171.0-181.3 Mb; Percent Open Arm Time: Chr1 151.7-180.5 Mb) 
and contains numerous genetic variants that could potentially underlie the 
behavioral effects.  However, the fundamental advantage of utilizing the RCC is 
the limited genetic diversity, resulting in fewer variants within the QTL interval 
than in a typical F2 cross of other inbred strains. For example, DBA/2J and 
C57BL/6J differ by 4.5 million single nucleotide polymorphisms (SNPs), whereas 
C57BL/6NJ and C57BL/6J differ by only approximately 10,000 SNPs (Simon et 
al., 2013).  As a comparison, in the distal chromosome 1 QTL hot spot interval 
(172-178 Mb) there are 23,723 SNPs within genes that differentiate DBA/2J from 
C57BL/6J and only 83 SNPs within genes that differentiate C57BL/6NJ from 
C57BL/6J. Therefore by utilizing the RCC, we were able to eliminate 99% of the 
genetic variants within the same size locus.  
 We focused this genetic variant comparison and our haplotype 
comparison to this region on distal chromosome 1 (Table 3.1) because it is a 
well-known QTL hotspot for neurobehavioral phenotypes (Mozhui et al., 2008). 
This region has been identified for numerous behaviors (DeFries, Gervais, & 
Thomas, 1978; Flint et al., 1995; Gershenfeld et al., 1997), including response to 
ethanol (Crabbe, 1996) and caffeine (Casley, Menzies, Whitehouse, & Moon, 
1999), utilizing B6J as a common reference strain (Mozhui et al., 2008). A 
compelling hypothesis is that the genetic variant that underlies the OXY 
behavioral QTL identified in our RCC is private to B6J and that the alternate 
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allele lies within a region that is identical by descent among the strains used to 
identify the neurobehavioral hotspot (Mozhui et al., 2008). We assessed shared 
genetic variants (SNPs and insertions/deletions) between C57BL/6NJ and these 
other strains (DBA/2J, BALB/cJ, C3/HeJ, LP/J; Table 3.1). In considering the 41 
overlapping variants within this region, only 12 variants were identified in all 
queried strains. These 12 variants reside within 7 genes. Importantly, overlapping 
variants were identified in 3 genes (Cadm3, Aim2, Rgs7) that were also denoted 
as high priority candidate genes from our transcriptome analysis.  
 We conducted transcriptome analysis in the striatum of a subset of OXY-
withdrawn F2 mice to prioritize candidate genes underlying behavioral QTLs, and 
to identify differentially expressed genes as a function of genotype within the QTL 
interval for OXY behaviors on distal chromosome 1. This combined approach has 
allowed us to identify strong candidate genes for the OXY sensitivity and 
withdrawal QTL on distal chromosome 1, including Aim2, Cadm3, and Rgs7 
(Table 3.2, Table 3.3, Figure 3.12). A top priority positional candidate for 
regulating these phenotypes is Rgs7, the expression of which significantly co-
varied with both OXY-induced locomotor activity and percent open arm time in 
the elevated plus maze (Fig 3.12). Importantly, deletion of Rgs7 has previously 
been shown to affect morphine reward and withdrawal and modulate synaptic 
plasticity (Sutton et al., 2016).  
 In addition to transcriptome analysis as a function of distal chr. 1 
genotype, we conducted eQTL analysis and identified cis-eQTLs that co-mapped 
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with additional behavioral QTLs. A noteworthy candidate gene for the variation in 
MA-induced locomotor activity (Fig. 3.10) is Gabra2. Gabra2 encodes the alpha2 
subunit of the GABA-A receptor. Genetic variants in Gabra2 are well-known for 
their association with alcoholism risk (Edenberg et al., 2004). Genetic variants in 
Gabra2 have previously been shown to modulate response to psychostimulants 
such as cocaine (Dixon et al., 2010; Duka et al., 2015), and more recently 
methyphenidate (Duka et al., 2015).  
 Transcriptome analysis is limited by the number of samples, brain regions, 
and time points that can be examined. Here, we utilized a subset of striatal 
samples from mice that were all assayed for OXY sensitivity and withdrawal. This 
design allowed us to (1) identify differential gene expression that may underlie 
differences in OXY sensitivity and withdrawal, and (2) to co-map cis-eQTLs for 
multiple addiction-associated behavioral phenotypes and (3) directly correlate 
behavior with expression levels. One limitation is that we cannot determine 
whether gene expression differences as a function of Genotype depend on prior 
treatment. Future studies utilizing both SAL- and OXY-treated samples are 
warranted. Another limitation was that we limited our focus to only one brain 
region, the striatum. Because we narrowed our focus primarily on our most 
robust QTL, which was associated with differential OXY-induced locomotor 
sensitivity, we chose to conduct transcriptome analysis in the striatum, a brain 
region integral to drug-induced locomotor sensitivity (Adinoff, 2004; Di Chiara & 
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Imperato, 1988). However, this may not represent the key brain region relevant 
to additional phenotypes, such as opioid withdrawal. 
 In addition to behavioral and expression QTL mapping, we further utilized 
the limited genetic diversity of the RCC to devise an efficient approach for fine 
mapping Mendelian traits (Fig. 3.6). Because of the nearly isogenic background 
of a B6JxB6NJ F2 mouse, we proposed that we could fine map a QTL for OXY 
behavioral sensitivity - a Mendelian trait - via backcrossing a subset of F2 mice 
possessing recombination events within the QTL interval, while ignoring 
genotype across the rest of the genome. The assumption was that the limited 
genetic diversity in the RCC F2 cross would result in minimal risk for epistatic 
interactions interfering with QTL detection. Using this strategy, we replicated our 
QTL finding and refined the proximal and distal boundaries. To our knowledge, 
this is the first time this approach has been utilized, and represents a unique 
advantage of the RCC.  
 A key question that remains is whether one locus or two separate loci 
underlie OXY sensitivity and withdrawal. Although the overlap of these QTL 
intervals is approximately 10 Mb (171.0-180.5 Mb), the interval for OXY 
withdrawal, as measured via the elevated plus maze, extends proximally to 151.7 
Mb which is 20 Mb more proximal than the OXY QTL (171.0 Mb). Future studies 
in F2 recombinants will further dissect these loci.  
 In summary, we replicated B6 substrain differences in psychostimulant-
induced locomotor activity and extended these differences to include opioid-
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induced locomotor activity. Using behavioral and expression QTL mapping in the 
reduced complexity cross we identified a QTL on chromosome 5 for MA-induced 
locomotor activity that co-mapped with a striatal cis-eQTL for Gabra2. We also 
identified a locus on distal chromosome 1 that regulates opioid-induced 
locomotor activity and withdrawal, a region containing a well-known 
neurobehavioral QTL ‘hotspot” (chr1: 172-178 Mb). Shared haplotype analysis of 
C57BL/6NJ and classical inbred strains combined with cis-eQTL analysis of F2 
mice identified three strong positional candidate genes for oxycodone behaviors - 
Cadm3, Aim2, and Rgs7. To conclude, we have utilized a systems genetics 
approach in the reduced complexity cross to rapidly identify compelling candidate 
genes underlying addiction traits.  
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CHAPTER 4: Discussion and Future Directions 
Summary 
 The focus of this dissertation was to investigate the genetic basis of 
addiction-associated traits with an emphasis on the aversive and rewarding 
properties of opioids. My personal interest lies in determining the genetic factors 
relevant to opioid abuse, which I believe is paramount for curbing the opioid 
epidemic. Opioids are highly effective pain relievers, have been used for 
centuries, and continue to be prescribed at high levels despite their large 
addiction liability. It is clear that there is a genetic component to risk for opioid 
addiction. However, at the present, these genetic risk factors are unknown but 
could prove useful in a precision medicine context when prescribing an opioid to 
an individual (e.g., dosing adjustment). Despite the complex behavioral pathology 
of addiction, identifying the genetic factors that mediate initial sensitivity to the 
positive effects of prescription opioids may be fundamental to identifying 
individuals who are at higher risk for opioid abuse, and ultimately adjust their pain 
treatment appropriately.  
 Here, we utilized both forward and reverse genetics in combination with 
transcriptomic and bioinformatic techniques as tools to identify the molecular 
pathways associated with differences in drug-induced behaviors. The two aims of 
this project combine forward genetics (Aim 1; Chapter 3) and reverse genetics 
(Aim 2; Chapter 2) to identify and validate candidate genes involved in complex 
addiction-associated traits.  
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 For the completion of Aim 1, we conducted a genetic linkage mapping 
study of addiction-associated traits in a reduced complexity cross (RCC) using 
C57BL6/J (B6J) and C57BL6/NJ (B6NJ) mouse strains. Additionally, we 
completed striatal transcriptome analyses to identify expression QTLs and 
differentially expressed genes relevant to differences in opioid sensitivity and 
withdrawal (Chapter 3).   
 For the completion of Aim 2, we investigated the role of Csnk1e in 
mediating opioid, psychostimulant, and sweetened palatable food reward. 
Additionally, we utilized striatal mRNA sequencing to generate novel hypotheses 
regarding the mechanism linking Csnk1e with drug-induced behaviors. 
Perspective  
 By and large, mouse geneticists have been successful at identifying QTL 
for complex traits. However, moving from QTL to QTG is the most challenging 
task. Despite thousands of QTLs being identified, very few genes meet the 
criteria for QTGs (Flint, Valdar, Shifman, & Mott, 2005; Korstanje & Paigen, 
2002). One reason for this is the need to establish causality. A fundamental 
advantage of genome-wide studies in mammalian model systems is the ability to 
establish causality. Numerous lines of evidence are necessary to confirm a QTG, 
and typically require positional cloning (i.e. fine mapping) or genetic 
complementation, techniques that are both time- and labor- intensive (Flint & 
Mott, 2001). 
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 An issue in moving from QTL to QTG is the number of variants within the 
QTL locus that may be responsible for variation in the trait. This goal can be 
accelerated by the use of mouse crosses, populations, and panels that have 
either an increase in the number of recombination events and/or reduced genetic 
complexity. In general, the field of mouse forward genetics has been moving 
towards utilizing mouse crosses that possess a larger number of recombination 
events (i.e. diversity outbred cross, outbred mice, etc.) as a solution to this issue 
(Gonzales & Palmer, 2014; Parker & Palmer, 2011; Williams & Williams, 2017). 
Due to the increased number of recombination events in these mapping 
populations (in comparison to an F2 cross) there is much higher mapping 
resolution, thereby decreasing the size of the QTL interval. An increase in the 
number of recombination events requires an increase in the number of genetic 
markers which in turn, requires a greater number of statistical tests to be 
performed, thus reducing power and increasing the required sample size. As an 
example, recent pioneering QTL mapping studies in outbred mice utilized from 
1000-2000 mice to identify QTLs explaining 5% of the variance in complex traits 
(Parker et al., 2016).  
 Here, rather than initially focusing on an increase in the number of 
recombination events, we took advantage of reduced genetic complexity to 
decrease the number of genetic variants under consideration for the QTLs we 
identified. Use of this cross recently led to the rapid identification of Cyfip2 as a 
genetic regulator of cocaine sensitivity (Kumar et al., 2013) and binge-like 
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consumption of palatable food (Kirkpatrick et al., 2016). Here, in combination with 
transcriptome analyses, we rapidly identified compelling candidate genes for 
multiple addiction-associated phenotypes. Additionally, we took advantage of the 
reduced genetic complexity of QTLs in the RCC (i.e., Mendelian QTLs) and as 
proof-of-principle, we executed a novel approach for fine mapping QTL using F2 
recombinants.  
 One of the (many) advantages of using a systems genetics approach is 
the wealth of data collected. Chapter 3 represents just a small portion of what 
can be accomplished and gleaned from the large transcriptome and behavioral 
datasets that we have collected in the RCC. Below, I will discuss future analyses 
that can utilize the existing datasets.  
Future Analyses 
 A key advantage of mouse behavioral studies is the ability to control 
environmental variable that can confound the link between genotype and 
behavior. It is not possible to remove or control for all external variables that may 
be influencing behavior. However, the large F2 behavioral dataset represents an 
opportunity to examine environmental variables that can interact with genes in 
modulating behavior. 
 Identifying gene by environment interactions is feasible in QTL mapping 
studies by treating environmental variables as covariates. One potential 
environmental variable that could be assessed would be within-cage “order of 
testing”. It was previously shown that the order that mice are taken out of the 
  
170
cage for experimental testing significantly affects morphine analgesia (Chesler, 
Wilson, Lariviere, Rodriguez-Zas, & Mogil, 2002a, 2002b). Indeed, it was this 
variable that eventually led to the discovery that mice exhibit empathy-like social 
contagion behaviors (Jordan & Mogil, 2006; Langford et al., 2006). It is possible 
that within-cage “order of testing” affects additional opioid behaviors. The F2 
behavioral dataset would allow for testing whether “order of testing” interacts with 
additional opioid behaviors, and if there is an interaction with genotype (or if 
controlling for this variable could improve existing QTL signals).  
 We completed two large transcriptome studies (naïve Csnk1e KO vs. WT 
striatum; striatum OXY-withdrawn F2 mice chosen based on genotype at the 
distal chromosome 1 QTL). We have utilized the F2 transcriptome analyses for 
initial expression QTL analyses and pathway analysis. One of the defining 
features of systems genetics is the emphasis on network analyses (Baliga et al., 
2017), and understanding how genes and intermediate biological phenotypes 
interact with each other. A next step for the transcriptome analyses would be to 
represent the relationships between transcript levels using “Weighted Gene Co-
expression Network Analysis” (WGCNA) (Langfelder & Horvath, 2008). It is also 
possible to then map these gene co-expression modules as quantitative traits, 
using module QTL mapping (Scott-Boyer, Haibe-Kains, & Deschepper, 2013), 
which may provide more information regarding trans-eQTLs (Mozhui et al., 2008) 
within the chromosome 1 QTL interval that could be regulating the expression of 
numerous genes collectively.  
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 Additionally, we chose to utilize 100 base pair paired-end sequencing in 
order to conduct spliceome as well as spliceQTL analyses (Monlong, Calvo, 
Ferreira, & Guigo, 2014). Splice variants are additional intermediate phenotypes 
that can be included in systems-level analysis. SpliceQTLs, regions of the 
genome that are causally associated with variation in splice variant expression, 
play a key role in mediating complex traits (Y. I. Li et al., 2016). SpliceQTL 
analyses would aid to the understanding of the functional effect of genetic 
variants underlying the identified behavioral QTLs.  
 A current limitation of our expression QTL analyses in the RCC (Chapter 
3) is the defined interval for cis-eQTLs. Cis-eQTLs are typically defined within a 1 
Mb or less interval to focus solely on the regions directly next to genes that may 
be regulatory in nature (Westra & Franke, 2014). However, we employed a cis-
eQTL boundary based on known genotypes (rather than inferred genotypes 
between markers), and due to our limited marker density as well as the limited 
number of recombination events in an F2 cross, there was a larger requirement 
for what could be defined as “cis”. However, because we utilized RNA-seq for our 
transcriptome analyses, it is possible to genotype coding variants and use them 
as additional markers to increase eQTL resolution (Deelen et al., 2015). 
Identification of additional genotype information within our QTL intervals by RNA-
seq may allow us to refine our cis-eQTL interval, and thus improve our 
confidence in our candidate genes.  
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Future Directions 
 One of the most exciting aspects of systems genetics is the hypothesis-
generating nature of the research, and thus there are multiple lines of research 
that can be developed based on the results. Through behavioral and expression 
QTL mapping, we identified numerous compelling candidate genes that can each 
be developed into independent lines of research. The ultimate question that 
remains from any QTL study is what are the QTGs and what are the quantitative 
trait nucleotides (QTNs).   
 A main focus of the continuation of this research will be in identifying the 
causal genetic factors mediating the QTL on chromosome 1 for both OXY 
sensitivity and withdrawal. Fine mapping using the F2 recombinants outlined in 
Chapter 3, will aid in identifying the causal genetic factors and answer whether 
one locus or multiple related loci are mediating multiple OXY phenotypes.  
 Numerous lines of evidence make Rgs7 a top priority candidate gene in 
this region of distal chromosome 1. We identified a cis-eQTL for Rgs7 and it was 
the only cis-eQTL for which gene expression correlated with OXY-induced 
locomotor activity and OXY withdrawal behaviors on the elevated plus maze. 
Importantly, recent studies have identified that knockdown of Rgs7 results in 
increased opioid reward and withdrawal (Sutton et al., 2016). 
 This region of chromosome 1 (172-178 Mb) is a well-known 
neurobehavioral QTL hot spot. The B6NJ strain shares variants (relative to B6J) 
within Rgs7 with other inbred strains that have identified loci on distal 
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chromosome 1. It is likely that the same causal variant(s) mediating the 
neurobehavioral QTL hot spot are shared with other behavioral QTLs from other 
inbred strains that have mapped to this locus. Future research could use 
CRISPR/Cas9 to develop an Rgs7 variant knock-in model. Based on the above 
hypothesis, shared variants within Rgs7 between B6NJ and the other inbred 
strains that were used to map to the locus on chromosome 1, could be knocked 
into a B6J mouse determine the effect on OXY-induced locomotor activity and 
withdrawal.  
 Rgs7 codes for the RGS7 protein, regulator of G-protein signaling 7, which 
deactivates GPCR signaling by accelerating the hydrolysis of GTP to GDP 
(Hollinger & Hepler, 2002). The main molecular target of opioids, the mu opioid 
receptor, is a GPCR. RGS7 has previously been shown to negatively regulate its 
activity (Fig 4.1).  
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Figure 4.1: The role of RGS7 in modulating opioid signaling.  
RGS7 modulates opioid signaling by accelerating GTP hydrolysis. Decreased 
functionality of RGS7 caused by variants within Rgs7 would result in increased 
signal from MOR. Adapted from (Sjogren, Blazer, & Neubig, 2010) 
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Therefore reducing RGS7 activity increases MOR signaling (REFS). 
Interestingly, we identified increased Rgs7 expression in F2 mice with the B6J 
allele, which exhibit increased OXY-induced locomotor activity. This seems 
contradictory to the findings of Sutton and colleagues (2016) who demonstrated 
that knockdown of Rgs7 resulted in increased opioid-induced behaviors. 
However, we have not examined the effect of genetic variation in Rgs7on RGS7 
protein levels and it is possible that increased transcription of Rgs7 could indicate 
a compensatory increase as a result of decreased protein expression (Fig 4.1). 
I.e., we may indeed observe the same negative relationship between opioid 
behaviors and Rgs7 expression at the protein level that was previously observed 
(Sutton et al., 2016).  
 An additional future area of research could be investigating the role of 
Gabra2 variants in methamphetamine-induced behaviors. We identified a cis-
eQTL for Gabra2 that co-mapped with methamphetamine-induced locomotor 
activity. Gabra2 encodes the alpha2 subunit of the GABA-A receptor. Genetic 
variants in Gabra2 are well-known for their association with alcoholism risk 
(Edenberg et al., 2004). Genetic variants in Gabra2 have previously been shown 
to modulate response to psychostimulants such as cocaine (Dixon et al., 2010; 
Duka et al., 2015), and more recently methylphenidate (Duka et al., 2015). A 
future direction would be to test the effect of functional variants within Gabra2 on 
methamphetamine-induced locomotor activity.  
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 Beyond candidate gene identification, an important outcome of the 
systems genetics approach was the identification of novel neurobiological 
pathways involved in addiction-associated traits. With regards to OXY sensitivity 
and withdrawal, we identified a pathway with APP (amyloid precursor protein) 
and MAPT (microtubule-associated protein tau) as hub genes. This presents a 
novel line of investigation. Currently, there is very little known regarding a role of 
MAPT or APP in response to drugs of abuse. However, an increase in 
hyperphosphorylated tau and APP deposition has been seen in the striatum of 
drug abusers (Ramage et al., 2005). Additionally, tau expression in the striatum 
is decreased following morphine treatment (Marie-Claire, Courtin, Roques, & 
Noble, 2004). A future line of research could involve investigating opioid 
behaviors in tau and APP knockout mice to investigate the relationship between 
these proteins and opioid behaviors. 
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